<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8001307</article-id><article-id pub-id-type="pmcid-ver">PMC8001307.1</article-id><article-id pub-id-type="pmcaid">8001307</article-id><article-id pub-id-type="pmcaiid">8001307</article-id><article-id pub-id-type="pmid">33807582</article-id><article-id pub-id-type="doi">10.3390/vaccines9030222</article-id><article-id pub-id-type="publisher-id">vaccines-09-00222</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Natural and Synthetic Saponins as Vaccine Adjuvants</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="P">Pengfei</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Wilson</surname><given-names initials="HL">Heather L.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-09-00222">Department of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA; <email>wangp@uab.edu</email></aff><pub-date pub-type="epub"><day>05</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2021</year></pub-date><volume>9</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">378379</issue-id><elocation-id>222</elocation-id><history><date date-type="received"><day>15</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>02</day><month>3</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>03</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>28</day><month>03</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-02 19:25:15.717"><day>02</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 by the author.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-09-00222.pdf"/><abstract><p>Saponin adjuvants have been extensively studied for their use in veterinary and human vaccines. Among them, QS-21 stands out owing to its unique profile of immunostimulating activity, inducing a balanced Th1/Th2 immunity, which is valuable to a broad scope of applications in combating various microbial pathogens, cancers, and other diseases. It has recently been approved for use in human vaccines as a key component of combination adjuvants, e.g., AS01b in Shingrix<sup>&#174;</sup> for herpes zoster. Despite its usefulness in research and clinic, the cellular and molecular mechanisms of QS-21 and other saponin adjuvants are poorly understood. Extensive efforts have been devoted to studies for understanding the mechanisms of QS-21 in different formulations and in different combinations with other adjuvants, and to medicinal chemistry studies for gaining mechanistic insights and development of practical alternatives to QS-21 that can circumvent its inherent drawbacks. In this review, we briefly summarize the current understandings of the mechanism underlying QS-21&#8217;s adjuvanticity and the encouraging results from recent structure-activity-relationship (SAR) studies.</p></abstract><kwd-group><kwd>adjuvant</kwd><kwd>saponin</kwd><kwd>mechanism</kwd><kwd>SAR</kwd><kwd>QS-21</kwd><kwd>VSA-1</kwd><kwd>VSA-2</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-09-00222"><title>1. Introduction</title><p>Traditional vaccines are whole-organism-based, using live attenuated or inactivated viruses or bacteria. These vaccines are quite reactogenic due to the presence of numerous pathogen-associated-molecular-patterns (PAMPs) that are responsible for activation, and sometimes over-activation, of the immune system. While being effective, the traditional vaccine development approach is inapplicable to combat against not only many other severe infection diseases, but also cancers and chronic inflammatory and autoimmune diseases [<xref rid="B1-vaccines-09-00222" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-09-00222" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-09-00222" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-09-00222" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-09-00222" ref-type="bibr">5</xref>]. The emergence of new pathogens and inadequate protection conferred by some of the existing vaccines, especially in certain age groups or in immunocompromised individuals highlights the need for more sophisticated and effective vaccines. One of the important developments in the field is subunit vaccines that employ well-characterized, highly purified, and safer antigens such as recombinant proteins and peptides. Subunit vaccines not only reduce side effects, but also provide a platform for exploring molecular mechanisms of the immune response. However, their highly refined antigens (thus with limited or no PAMPs) do not activate as many facets of the immune response as whole-organism-based vaccines. The poor immunogenicity generally leads to stimulation of a weak and short-lived immunity. To boost immunogenicity, it is crucial for subunit vaccines to have immunostimulatory adjuvants that enhance immune responses induced by the poorly immunogenic antigens.</p><p>Vaccine adjuvants are non-immunogenic substances that can improve or modulate antigen-specific immune responses toward their co-administered antigens, constituting an indispensable element of modern vaccines [<xref rid="B6-vaccines-09-00222" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-09-00222" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-09-00222" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-09-00222" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-09-00222" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-09-00222" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-09-00222" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-09-00222" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-09-00222" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-09-00222" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-09-00222" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-09-00222" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-09-00222" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-09-00222" ref-type="bibr">19</xref>]. They can (a) enhance the ability of a vaccine to elicit strong and durable immune responses (including in immunologically compromised individuals such as immunologically immature (neonates), aged, and immune suppressed individuals) [<xref rid="B20-vaccines-09-00222" ref-type="bibr">20</xref>], (b) reduce antigen dose and the number of immunizations, and (c) modulate the nature of immune response (e.g., in favor of humoral or cell-mediated response). Despite the increasingly important role of adjuvants, there only a few adjuvants approved for human use [<xref rid="B15-vaccines-09-00222" ref-type="bibr">15</xref>,<xref rid="B18-vaccines-09-00222" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-09-00222" ref-type="bibr">19</xref>,<xref rid="B21-vaccines-09-00222" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-09-00222" ref-type="bibr">22</xref>]. Alum (various aluminum salts), the first and most commonly used adjuvant, had been the only human vaccine adjuvant for more than nine decades until 2009 [<xref rid="B23-vaccines-09-00222" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-09-00222" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-09-00222" ref-type="bibr">25</xref>]. It primarily enhances Th2 humoral responses, effective for neutralizing vaccines, but ineffective for vaccines targeting intracellular pathogens or cancer cells when a Th1 or mixed Th1/Th2 response is required. Moreover, alum is not compatible for mucosal vaccines. In 2009, Food and Drug Administration (FDA) approved AS04, a combination of alum and monophosphoryl lipid A (MPLA), for human use [<xref rid="B26-vaccines-09-00222" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-09-00222" ref-type="bibr">27</xref>]. MPLA was the first Toll-like receptor (TLR) agonist approved for human vaccine. Since 2016, FDA has approved three more adjuvants (i.e., MF59/AS03, CpG 1018, and AS01b). MF59/AS03 is a squalene-based oil-in-water emulsion used in influenza vaccines [<xref rid="B28-vaccines-09-00222" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-09-00222" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-09-00222" ref-type="bibr">30</xref>]. CpG 1018 is a TLR9 agonist used in a Hepatitis B vaccine; it is a short, 22-base synthetic oligonucleotide mimicking bacterial and viral genetic material [<xref rid="B31-vaccines-09-00222" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-09-00222" ref-type="bibr">32</xref>]. AS01b was approved recently for use in Shingrix<sup>&#174;</sup> against herpes zoster by FDA [<xref rid="B33-vaccines-09-00222" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-09-00222" ref-type="bibr">34</xref>] and Mosquirix<sup>&#174;</sup> against malaria by European Medicines Agency (EMA) [<xref rid="B35-vaccines-09-00222" ref-type="bibr">35</xref>]. It is a combination adjuvant containing MPLA and saponin QS-21 in a liposomal formulation that induces strong humoral and cellular immune responses [<xref rid="B33-vaccines-09-00222" ref-type="bibr">33</xref>,<xref rid="B36-vaccines-09-00222" ref-type="bibr">36</xref>].</p></sec><sec id="sec2-vaccines-09-00222"><title>2. Immunostimulatory Adjuvant QS-21</title><p>QS-21 is a mixture of two isomeric bidesmosidic saponins (1, <xref ref-type="fig" rid="vaccines-09-00222-f001">Figure 1</xref>), isolated from the tree bark of <italic toggle="yes">Quillaja saponaria</italic> Molina (QS), an evergreen tree native to temperate central Chile. It can potentiate a balanced Th1/Th2 response with antigen-specific cytotoxic T lymphocyte (CTL) production [<xref rid="B37-vaccines-09-00222" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-09-00222" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-09-00222" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-09-00222" ref-type="bibr">40</xref>].</p><p>QS-21 has a triterpene aglycone core, quillaic acid, with a branched trisaccharide connecting to the C3 OH group through a beta glycosidic ether bond, and a linear tetrasaccharide connecting to the C28 carboxyl group through a beta glycosidic ester bond (<xref ref-type="fig" rid="vaccines-09-00222-f001">Figure 1</xref>). The reducing end of the C28 tetrasaccharide is a <italic toggle="yes">&#946;</italic>-<sc>d</sc>-fucosyl unit with its 4-O position capped with a glycosylated pseudodimeric fatty acyl chain. The two structural isomers of QS-21 only differ in the nonreducing end of the C28 tetrasaccharide, i.e., QS-21<sub>api</sub> (~65% abundance) has a terminal <italic toggle="yes">&#946;</italic>-<sc>d</sc>-apiosyl unit while QS-21<sub>xyl</sub> (~35% abundance) has a terminal <italic toggle="yes">&#946;</italic>-<sc>d</sc>-xylosyl unit. The structure of the two isomers were confirmed by Gin et al. with organic synthesis [<xref rid="B41-vaccines-09-00222" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-09-00222" ref-type="bibr">42</xref>]. The two isomers have similar adjuvant activity and toxicity [<xref rid="B43-vaccines-09-00222" ref-type="bibr">43</xref>].</p><p>QS-21 is amphipathic with its hydrophobic (triterpene core and fatty acyl chain) and hydrophilic (sugar) moieties. The amphipathicity can cause permeation of cell membranes, which was attributed to its intrinsic lytic activity and cytotoxicity [<xref rid="B39-vaccines-09-00222" ref-type="bibr">39</xref>,<xref rid="B44-vaccines-09-00222" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-09-00222" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-09-00222" ref-type="bibr">46</xref>]. Melzig et al. suggested that the general cytotoxicity of saponins was mainly dependent on their membrane toxicity, which might be caused by the loss of cholesterol from the cell membrane [<xref rid="B47-vaccines-09-00222" ref-type="bibr">47</xref>]. The lytic activity of QS saponins can be reduced significantly through proper formulation, such as in liposomes in the presence of cholesterol (e.g., AS01), in emulsions (e.g., AS02), or in ISCOMATRIX (IMX) with phospholipid and cholesterol [<xref rid="B48-vaccines-09-00222" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-09-00222" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-09-00222" ref-type="bibr">50</xref>]. It was suggested that saponins might interact with membranes in a cholesterol-dependent manner, leading to pore formation [<xref rid="B51-vaccines-09-00222" ref-type="bibr">51</xref>,<xref rid="B52-vaccines-09-00222" ref-type="bibr">52</xref>]. Korchowiec et al. recently demonstrated that two structurally different saponins, digitonin and Merck saponin, showed high affinity for cholesterol in lipid model membranes by using Langmuir monolayer techniques combined with polarization modulation infrared reflection-absorption spectroscopy (PM-IRRAS) and Brewster angle microscopy [<xref rid="B53-vaccines-09-00222" ref-type="bibr">53</xref>]. However, amphipathicity is probably not responsible for QS-21&#8217;s unique adjuvant activity in that most of amphipathic saponins do not have QS-21&#8217;s superb immune stimulating activity [<xref rid="B54-vaccines-09-00222" ref-type="bibr">54</xref>]. QS-21&#8217;s amphipathicity can also lead to micelle formation in aqueous solutions [<xref rid="B55-vaccines-09-00222" ref-type="bibr">55</xref>], for example, it has a critical micelle concentration (CMC) at 51 &#181;g/mL in succinate buffered aqueous solutions. However, QS-21&#8217;s adjuvanticity seems to be irrelevant to micelle formation in that it remains active at concentrations below the CMC [<xref rid="B56-vaccines-09-00222" ref-type="bibr">56</xref>].</p><p>Along with QS-21, there are three other structurally characterized saponins in the same tree bark extract, i.e., QS-7 (<bold>2</bold>), QS-17 (<bold>3</bold>), and QS-18 (<bold>4</bold>) (<xref ref-type="fig" rid="vaccines-09-00222-f002">Figure 2</xref>) [<xref rid="B37-vaccines-09-00222" ref-type="bibr">37</xref>,<xref rid="B39-vaccines-09-00222" ref-type="bibr">39</xref>]. QS-7 (<bold>2</bold>, <xref ref-type="fig" rid="vaccines-09-00222-f002">Figure 2</xref>) has adjuvant activity similar to QS-21 but lower toxicity [<xref rid="B57-vaccines-09-00222" ref-type="bibr">57</xref>]. Its structure is significantly different from the other three characterized QS saponins: It does not bear a glycosylated pseudodimeric acyl side chain in the C28 oligosaccharide domain. Gin et al. confirmed the structure of natural QS-7 via organic synthesis in 2008 [<xref rid="B58-vaccines-09-00222" ref-type="bibr">58</xref>]. The respective fatty acyl chain of QS-17, 18, and 21 was believed to be responsible for their capability of stimulating cellular immunity [<xref rid="B55-vaccines-09-00222" ref-type="bibr">55</xref>,<xref rid="B59-vaccines-09-00222" ref-type="bibr">59</xref>]. QS-18 is the most abundant saponin in the QS Molina tree bark extract. The main structural difference between QS-17/18 and QS-21 is in the C28 oligosaccharide domain. Instead of having a linear tetrasaccharide as in QS-21, QS-17/18 has an additional <italic toggle="yes">&#946;</italic>-<sc>d</sc>-glucopyranosyl (glc) unit connected to the <italic toggle="yes">&#945;</italic>-L-rhamnopyranosyl (rha) unit at its 3-O position. QS-17 differs from QS-18 only in the R<sup>2</sup> group of the acyl side chain, i.e., QS-17 has a disaccharide unit while QS-18 has a monosaccharide unit at the far end of the side chain (<xref ref-type="fig" rid="vaccines-09-00222-f002">Figure 2</xref>). These three QS saponins have a similar adjuvant activity profile but QS-17 and QS-18 are more toxic than QS-21. The higher toxicity of QS-18 than that of QS-21 was attributed to the extra glc branch in the C28 oligosaccharide domain; however, QS-7, with the same branch at the same site, is notably less toxic than QS-21. These observations suggest that immunostimulating activity and toxicity of these saponins are probably determined by each individual saponin&#8217;s specific molecular structure instead of by the presence/absence of a certain structural feature in the saponin or by its amphipathicity.</p><p>QS-21 has been extensively studied in the form of a combination adjuvant [<xref rid="B60-vaccines-09-00222" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-09-00222" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-09-00222" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-09-00222" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-09-00222" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-09-00222" ref-type="bibr">65</xref>]. It is a key component of the GlaxoSmithKline&#8217;s Adjuvant System AS01 (including the FDA-approved AS01b), AS02 (an oil-in-water emulsion containing QS21 and MPL), AS05 (liposomes containing QS21, MPL, and alum), and AS15 (liposome formulation containing QS-21, MPL, and CpG) [<xref rid="B34-vaccines-09-00222" ref-type="bibr">34</xref>,<xref rid="B63-vaccines-09-00222" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-09-00222" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-09-00222" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-09-00222" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-09-00222" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-09-00222" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-09-00222" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-09-00222" ref-type="bibr">70</xref>]. These systems are effective in enhancing both humoral and cellular immunogenicity of different types of antigens in human subjects [<xref rid="B66-vaccines-09-00222" ref-type="bibr">66</xref>,<xref rid="B69-vaccines-09-00222" ref-type="bibr">69</xref>] and can also be effective for certain patient populations [<xref rid="B67-vaccines-09-00222" ref-type="bibr">67</xref>]. The QS-21-containing combination adjuvants have been recently reviewed [<xref rid="B26-vaccines-09-00222" ref-type="bibr">26</xref>,<xref rid="B33-vaccines-09-00222" ref-type="bibr">33</xref>,<xref rid="B36-vaccines-09-00222" ref-type="bibr">36</xref>], and they will not be discussed in this review.</p></sec><sec id="sec3-vaccines-09-00222"><title>3. Mechanism Studies of QS-21</title><p>In general, vaccine adjuvants can first help to create a proper local immune environment at the injection site(s) by activating innate immune responses, which are responsible for the development of the subsequent adaptive immune responses [<xref rid="B12-vaccines-09-00222" ref-type="bibr">12</xref>,<xref rid="B71-vaccines-09-00222" ref-type="bibr">71</xref>]. Currently known mechanisms of action of adjuvants include (a) sustaining release of antigens at the injection site, (b) modulating production of cytokines and chemokines, (c) recruiting of immune cells to the injection site to create a proper local immune environment, (d) upregulating the expression of Major Histocompatibility Complex (MHC)-I and/or MHC-II and co-stimulatory signals CD40, CD80/86 on the surface of antigen-presenting cells (APCs), (e) enhancing antigen processing and expression by APCs, (f) facilitating migration of the mature APCs to the draining lymph nodes (dLNs), (g) helping activation of antigen-specific B or T cells through their interaction with mature APCs to produce proper B cells, CD4+, and/or effector CD8+ T cell responses [<xref rid="B72-vaccines-09-00222" ref-type="bibr">72</xref>].</p><p>The mechanism underneath QS-21&#8242;s adjuvanticity remains largely unknown despite its wide use in various experimental vaccines and its approval for clinic use [<xref rid="B35-vaccines-09-00222" ref-type="bibr">35</xref>]. It is unclear whether QS-21 activates immune cells via a specific receptor and what particular signaling pathways are responsible for its extraordinary immunostimulating activity. However, efforts in elucidating its mechanism have led to valuable insights.</p><p>It is known that QS-21 does not operate by a depot effect to extend presentation of the co-administered antigen to the immune system [<xref rid="B37-vaccines-09-00222" ref-type="bibr">37</xref>]. Reimer et al. used an adjuvant formulation containing natural QS saponins, i.e., Matrix-M<sup>TM</sup>, to study its role in stimulating immune responses in BALB/c mice [<xref rid="B73-vaccines-09-00222" ref-type="bibr">73</xref>]. Matrix-M<sup>TM</sup> is comprised of 40 nm nanoparticles made of <italic toggle="yes">Quillaja</italic> saponins, cholesterol, and phospholipids [<xref rid="B50-vaccines-09-00222" ref-type="bibr">50</xref>,<xref rid="B74-vaccines-09-00222" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-09-00222" ref-type="bibr">75</xref>]. In the absence of antigen, the adjuvant led to a local transient immune response with recruitment and activation of central immune cells to dLNs 48 h post subcutaneous injection. These effects might play a role in enhancing uptake and presentation of vaccine antigens to elicit a competent immune response. By using synthetic QS-21 analogs as molecular probes, Tan, Lewis, and Ragupathi et al. suggested their synthetic QS-21 analogs had a potential role in facilitating antigen trafficking by APCs from the site of injection to the dLNs, where the processed antigens are presented to the adaptive immune system [<xref rid="B76-vaccines-09-00222" ref-type="bibr">76</xref>]. However, the molecular structure of the employed saponin probes is significantly different from that of QS-21, and it is unclear whether the synthetic analogs inherited the same adjuvant activity profile and thus the same mechanism of QS-21. Thus, the observations with the synthetic probes might not be extrapolated to natural QS-21.</p><p>Newman et al. showed through in vivo and in vitro cell depletion and reconstitution studies that macrophages could be an important site of action for QS-21 [<xref rid="B77-vaccines-09-00222" ref-type="bibr">77</xref>]. Recently, by using QS-21 formulated in liposomes with Hepatitis B surface antigen (HBsAg) or ovalbumin (OVA) antigen, Goriely and Didierlaurent et al. observed that intramuscular immunization in mice led to a rapid local innate response in the dLN. They identified CD169+ resident macrophages of the lymph node draining the injection site as the main cells targeted by QS-21 in formulation with liposomes. QS-21 accumulated rapidly in CD169+ resident macrophages of the dLN, where it induced Caspase-1 activation and caused the release of high-mobility group protein B1 (HMGB1). These early events led to the recruitment of innate immune cells and activation of dendritic cells (DCs) which then presumably triggered MyD88-dependent activation of antigen-specific cellular and humoral responses. The adjuvant effect of QS-21 depended on the integration of Caspase-1 and MyD88 pathways, at least in part through the local release of HMGB1 [<xref rid="B78-vaccines-09-00222" ref-type="bibr">78</xref>]. Depletion of these CD169+ resident macrophages abrogated QS-21-mediated innate cell recruitment to the lymph node, DC phenotypic maturation as well as the adjuvant effect on T-cell and antibody responses to co-administered antigens.</p><p>Regarding DC activation, it is known that QS-21 does not bind to Toll-like receptors 2 and 4 [<xref rid="B79-vaccines-09-00222" ref-type="bibr">79</xref>]. Marciani et al. suggested that QS-21 would be unlikely to activate DCs by interacting directly with specific cell receptors. Instead, <italic toggle="yes">Quillaja</italic> saponins (including QS-21) probably could act on DCs in a non-receptor-mediated manner [<xref rid="B80-vaccines-09-00222" ref-type="bibr">80</xref>]. QS-21 could facilitate the entry of exogenous protein antigens into DCs by cholesterol-dependent endocytosis [<xref rid="B80-vaccines-09-00222" ref-type="bibr">80</xref>]. It then would disrupt the endosomal membrane to facilitate early escape of the antigens for further processing inside the cell. The processed antigen fragments would be loaded into MHC I and cross-presented on the DC surface to initiate production of CTLs.</p><p>Goriely et al. recently reported that QS-21 directly activated human monocyte-derived dendritic cells (moDCs) and promoted a pro-inflammatory transcriptional program [<xref rid="B81-vaccines-09-00222" ref-type="bibr">81</xref>]. Thus, QS-21 entered DCs via a cholesterol-dependent endocytosis, and then destabilized lysosomes through pore formation, causing release of their contents including lysosomal enzymes, which resulted in inflammasome activation, Syk- (a tyrosine kinase) and cathepsin-B- (a cysteine protease) dependent cell activation and cytokine production in moDCs. Their results suggested that cytokine production by QS-21-stimulated moDCs did not depend on inflammasome activation. However, some results were drawn using molecular probes such as BODIPY-QS-21 (a boron-dipyrromethene and QS-21 conjugate) and <sup>14</sup>C-QS-21 (structure unrevealed) whose adjuvant activities were not fully characterized against QS-21. It is known that structural modification of QS-21 could significantly alternate its adjuvant property and thus mechanism. In order to ensure their results relevant to QS-21, it is important to confirm that the adjuvant activity profiles of the synthetic probes closely resemble that of QS-21. In a related study, Melzig et al. analyzed the influence of a significantly membrane toxic saponin on the cholesterol content of intracellular membranes such as those of endosomes and lysosomes, and found that a membrane toxicity mechanism featuring the saponin-dependent loss of membrane cholesterol was not detectable on the endosome/lysosome membrane [<xref rid="B47-vaccines-09-00222" ref-type="bibr">47</xref>].</p><p>Adema et al. noticed saponin adjuvants could induce cross-presentation in DCs by intracellular lipid body (LB) formation [<xref rid="B82-vaccines-09-00222" ref-type="bibr">82</xref>], which could be relevant to QS-21&#8217;s mechanism. LB organelles consist of a phospholipid monolayer that contains numerous proteins and a core of neutral lipids, such as sterol esters or triacylglycerols. <italic toggle="yes">QS</italic> saponins (containing QS-21) in the form of ISCOM induced intracellular LB formation only in the CD11b+ DC subset in vitro and in vivo. LB formation was positively related to the enhanced cross-presentation of antigens and T-cell activation [<xref rid="B83-vaccines-09-00222" ref-type="bibr">83</xref>]. LBs facilitated the proteasomal route of cross-presentation and blockade of LB induction effectively abrogated the saponin-induced antigen cross-presentation.</p><p>Inflammasomes are an essential part of the innate immune system and their activation can stimulate the adaptive immune system; thus, they are often the targets for vaccine adjuvants [<xref rid="B84-vaccines-09-00222" ref-type="bibr">84</xref>]. The role of QS-21 in activating NOD-like receptor protein 3 (NLRP3) inflammasome seems to be complicated. On one hand, Lien et al. observed that QS-21 itself did not activate NLRP3 inflammasome and the subsequent production of cytokines IL-1&#946; or IL-18 in bone marrow-derived dendritic cells (BMDCs) or immortalized mouse macrophages, unless paired with MPLA. Moreover, NLRP3-deficient mice immunized with HIV-1 gp120 and QS-21 showed significantly higher levels of Th1 and Th2 antigen-specific T cell responses and higher IgG1 and IgG2c activities than the wild-type controls [<xref rid="B85-vaccines-09-00222" ref-type="bibr">85</xref>]. On the other hand, Goriely and Didierlaurent et al. observed QS-21 formulated in liposomes induced NLRP3 inflammasome activation and Caspase-1-dependent production of IL-1&#946;, suggesting that NLRP3 activation was involved in QS-21-induced immune responses such as innate cell recruitment and both CD4 and CD8 T-cell responses [<xref rid="B78-vaccines-09-00222" ref-type="bibr">78</xref>].</p><p>In a related study, Morelli and Schnurr et al. evaluated immune cell responses to <italic toggle="yes">Quil</italic> A (purified <italic toggle="yes">QS</italic> saponins, containing QS-21) in the form of IMX in mice [<xref rid="B86-vaccines-09-00222" ref-type="bibr">86</xref>]. IMX is comprised of phospholipid, <italic toggle="yes">Quil</italic> A, and cholesterol components that form cage-like structures &#8764;40 nm in diameter [<xref rid="B48-vaccines-09-00222" ref-type="bibr">48</xref>]. The complex was identified as a potent activator of the NLRP3 inflammasome in APCs in vitro, leading to IL-1&#946; and IL-18 production; however, both inflammasome-related and -unrelated pathways contributed to IL-18-dependent IMX-mediated NK cell activation and vaccine-induced cytotoxic T cells and B cell immunity in vivo. NLRP3 was dispensable for induction of NK or T cell immune responses.</p><p>Regarding activation of T cells, Kensil et al. postulated that QS-21 might stimulate T cells via receptor-mediated mechanisms [<xref rid="B87-vaccines-09-00222" ref-type="bibr">87</xref>,<xref rid="B88-vaccines-09-00222" ref-type="bibr">88</xref>]. They suggested that QS-21 could build a chemical bond by using its carbonyl group of the quillaic acid triterpene core to react with an amino group of putative T-cell surface receptors. This chemical event could provide co-stimulation signals for T-cell activation, an analogy to the previous observation with tucaresol, which is a carbonyl-containing small molecule, believed to send costimulatory signals to the CD4+ T cell via the chemical event of forming Schiff base on T-cell surface amines through its aldehyde moiety [<xref rid="B89-vaccines-09-00222" ref-type="bibr">89</xref>]. In the presence of tucaresol, stimulation of the T cells with anti-CD3 led to a five- to tenfold enhancement of IL-2 production. However, there lacks direct experimental evidence to confirm that QS-21 can effectively form Schiff base on T cell surface, albeit there is indirect evidence from the studies of Kensil et al. showing that chemical modification of the quillaic acid carbonyl group resulted in severely diminished adjuvant activity of QS-21 [<xref rid="B88-vaccines-09-00222" ref-type="bibr">88</xref>].</p></sec><sec id="sec4-vaccines-09-00222"><title>4. Structure-Activity-Relationship (SAR) Studies of QS-21</title><p>QS-21 has been proved to be a unique and potent adjuvant for applications in clinical and experimental vaccines, even though its detailed cellular and molecular mechanisms remain largely unknown. Parallel to the efforts of expanding its application and exploring its mechanism, extensive medicinal chemistry efforts have been devoted to its SAR studies, aiming at gaining mechanistic insights, and developing molecular probes and practical QS-21 alternatives that are devoid of its inherent drawbacks [<xref rid="B19-vaccines-09-00222" ref-type="bibr">19</xref>,<xref rid="B90-vaccines-09-00222" ref-type="bibr">90</xref>]. For example, abundance of QS-21 in <italic toggle="yes">QS</italic> tree bark extracts is low [<xref rid="B91-vaccines-09-00222" ref-type="bibr">91</xref>], and overexploitation of the natural source has resulted in ecological damage and shortage of available supplies even under the current demand, leading to more strict environmental regulations and increased price [<xref rid="B92-vaccines-09-00222" ref-type="bibr">92</xref>]. It was estimated that the current global supply of natural QS-21 was only enough for approximately 6 million doses (100 &#956;g/dose for human use) [<xref rid="B93-vaccines-09-00222" ref-type="bibr">93</xref>], not sufficient for widespread clinical use for various anti-infective vaccines. QS-21&#8242;s adjuvanticity increases with dose, however, its dose-limited side effects prevent it from reaching its full potential. Early SAR studies indicated that adjuvanticity and toxicity of <italic toggle="yes">QS</italic> saponins could be decoupled, and toxicity of <italic toggle="yes">QS</italic> saponins could be independently modulated through specific structural modifications while maintaining potent adjuvant activity [<xref rid="B94-vaccines-09-00222" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-09-00222" ref-type="bibr">95</xref>]. The limited supply of QS-21, along with its dose-limiting toxicity, chemical instability, and laborious and low-yielding purification, hinder its wider use [<xref rid="B92-vaccines-09-00222" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-09-00222" ref-type="bibr">93</xref>]. There is an imperative need for potent and practical alternatives to QS-21 that are more potent and less toxic [<xref rid="B96-vaccines-09-00222" ref-type="bibr">96</xref>].</p><p>It was suggested that QS-21 could interact with immune cells in a receptor-mediated or a non-receptor-mediated manner. SAR studies indicate a receptor-mediated interaction could play a crucial role in that saponins with the same or similar hydrophile&#8722;lipophile balance (HLB), but only subtle structural differences show significantly different adjuvant activities.</p><p>Some structural features of QS-21 have been identified as being relevant to its adjuvant activity, e.g., the C23 aldehyde moiety of the quillaic acid core and the fatty acyl side chain that caps O-4 of the fucosyl unit at the reducing end of the C28 oligosaccharide. It has been postulated that the carbonyl group forms a Schiff base with an amino group of putative T-cell surface receptors to provide co-stimulation for T-cell activation [<xref rid="B80-vaccines-09-00222" ref-type="bibr">80</xref>,<xref rid="B89-vaccines-09-00222" ref-type="bibr">89</xref>]. The hypothesis is supported by the observations that (a) saponins lacking such an aldehyde group are devoid of these activities, and (b) chemical modification of the aldehyde group results in loss of adjuvant activities. Moreover, some other saponins bearing a carbonyl group in their respective structure also show immunostimulating properties, e.g., gypenosides from the Cucurbitaceae <italic toggle="yes">Gynostemma pentaphyllum</italic>, and curculigosaponin G from the rhizomes of <italic toggle="yes">Curculigo orchioides</italic> [<xref rid="B97-vaccines-09-00222" ref-type="bibr">97</xref>]. However, there are also plenty of saponins capable of stimulating immune responses, including cellular responses in the absence of such a carbonyl group, e.g., ginsenosides [<xref rid="B97-vaccines-09-00222" ref-type="bibr">97</xref>]. There are also saponins that have structure similar to that of QS-21, but show no immunostimulating properties. For example, the triterpene glycosides (<bold>5</bold>, <xref ref-type="fig" rid="vaccines-09-00222-f003">Figure 3</xref>) isolated from <italic toggle="yes">Silene jenisseensis</italic> (Caryophyllacea) [<xref rid="B98-vaccines-09-00222" ref-type="bibr">98</xref>] have the identical quillaic acid triterpene core to QS-21, and similar to QS-21, it has a fatty acyl group (i.e., <italic toggle="yes">trans- or cis</italic>-<italic toggle="yes">p</italic>-methoxycinnamoyl group) on the fucose residue of the C28 oligosaccharide reducing end. These examples suggest that it is probably the specific structure of the whole saponin molecule that determines its adjuvant properties. Structurally similar saponins with the &#8220;key&#8221; functional groups of QS-21, e.g., C3 oligosaccharide, C16 hydroxyl group, C23 carbonyl group, C28 oligosaccharide, and its reducing end fucosyl unit capped with a fatty acyl chain at 4-O, will not be warranted with adjuvant activities similar to that of QS-21. Another relevant evidence supporting that saponins&#8217; adjuvant activity may rely on receptor-mediated interactions rather than saponins&#8217; amphiphilicity or their possession of certain functional groups was demonstrated by saikosaponins (<bold>6</bold>, <xref ref-type="fig" rid="vaccines-09-00222-f003">Figure 3</xref>). Saikosaponins have a stimulatory effect on macrophage activation, with saikosaponin-d (<bold>6&#945;</bold>) being more effective than saikosaponin-a (<bold>6&#946;</bold>). These two saponins differ only in their stereo-configuration at C-16 [<xref rid="B99-vaccines-09-00222" ref-type="bibr">99</xref>].</p><p>QS-21 is one of the rare saponins bearing an acyl side chain. The specific role of the acyl group remains unclear, but SAR studies proved that it was crucial to the potent activity of QS-21 in stimulating a Th1 immunity [<xref rid="B55-vaccines-09-00222" ref-type="bibr">55</xref>,<xref rid="B59-vaccines-09-00222" ref-type="bibr">59</xref>]. Removal of the acyl group led to QS-21&#8217;s loss of its ability in stimulating a lymphoproliferative response and CTL production, but the deacylated QS-21 remained active in potentiating Th2 responses [<xref rid="B59-vaccines-09-00222" ref-type="bibr">59</xref>,<xref rid="B100-vaccines-09-00222" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-09-00222" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-09-00222" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-09-00222" ref-type="bibr">103</xref>]. It was postulated that by removing the acyl group, the reducing end fucosyl unit of the C28 oligosaccharide would be exposed for its putative interaction with dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptors on DC, inducing a Th2-skewed immunity [<xref rid="B104-vaccines-09-00222" ref-type="bibr">104</xref>]. It remains to be proven that the internal fucosyl unit is capable of binding to DC-SIGN, which is only known for binding with a terminal fucosyl unit or other types of sugars [<xref rid="B105-vaccines-09-00222" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-09-00222" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-09-00222" ref-type="bibr">107</xref>,<xref rid="B108-vaccines-09-00222" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-09-00222" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-09-00222" ref-type="bibr">110</xref>,<xref rid="B111-vaccines-09-00222" ref-type="bibr">111</xref>]. Even if the presumed binding event is responsible for the Th2-only immunity induced by the deacylated QS-21, the fatty acyl chain of the natural QS-21 is more than just blocking its binding with DC-SIGN. In fact, synthetic QS analog <bold>7</bold> (<xref ref-type="fig" rid="vaccines-09-00222-f004">Figure 4</xref>) with the natural acyl side chain replaced with a simple acetyl group should still block the fucosyl/DC-SIGN binding; however, it showed inferior adjuvant activity to that of QS-21 and a much lower IgG2a/IgG1 ratio (indicating its induction of a less Th-1 skewed immunity) [<xref rid="B112-vaccines-09-00222" ref-type="bibr">112</xref>]. Since production of IgG1 or IgG2a in mice is enhanced by the respective Th2 or Th1 cytokines, the relative amount of IgG2a and IgG1 was often used as a tentative indication of involvement of Th1 and Th2 immunity potentiated by the adjuvant. Interestingly, by adding one glc unit to saponin <bold>7</bold> at the particular position boosted adjuvant activity of the resulting new saponin <bold>8</bold> (structurally resembling QS-7 more than QS-21) in terms of enhancing IgG, IgG1, and IgG2a production to the same level as QS-21, and a similar IgG2a/IgG1 ratio as well (<xref ref-type="fig" rid="vaccines-09-00222-f004">Figure 4</xref>) [<xref rid="B112-vaccines-09-00222" ref-type="bibr">112</xref>].</p><p>Marciani et al. developed the semi-synthetic saponin analog GPI-0100 [<xref rid="B100-vaccines-09-00222" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-09-00222" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-09-00222" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-09-00222" ref-type="bibr">103</xref>,<xref rid="B113-vaccines-09-00222" ref-type="bibr">113</xref>]. It was prepared from <italic toggle="yes">Quil</italic> A, a purified mixture of complex QS tree bark extracts (containing QS-17, -18, -21, and numerous other saponins), by complete removal of the acyl side chain and subsequent incorporation of a dodecylamine chain via amide formation. The resulting complex mixture, GPI-0100, retains the capacity of stimulating humoral and cellular immunity. It is 20 times less lethal in mice than QS-21. In a study of a prostate cancer vaccine, GPI-0100 was found to be more potent than QS-21 in mice at doses that were less toxic [<xref rid="B114-vaccines-09-00222" ref-type="bibr">114</xref>]. The immunological property of GPI-0100, especially its retained capacity of stimulating a cellular immunity, indicated the important role of a side chain in inducing a Th1 immunity. It also indicated that it was not crucial to have the side chain cap the fucosyl unit as in natural QS-21.</p><p>Wang et al. synthesized unnatural analogs of QS-21, e.g., <bold>9</bold>&#8211;<bold>12</bold> (<xref ref-type="fig" rid="vaccines-09-00222-f005">Figure 5</xref>) [<xref rid="B115-vaccines-09-00222" ref-type="bibr">115</xref>,<xref rid="B116-vaccines-09-00222" ref-type="bibr">116</xref>]. Similar to GPI-0100, they have an aliphatic chain connected to the C3 trisaccharide domain through a chemically stable amide bond instead of an acyl side chain as in QS-21. The results showed that saponins <bold>10</bold>&#8211;<bold>12</bold>, and especially <bold>10</bold> and <bold>11</bold>, were effective in potentiating a serum antigen-specific IgG response following systemic immunization [<xref rid="B80-vaccines-09-00222" ref-type="bibr">80</xref>]. Analysis of the IgG2a/IgG1 ratio of the antigen-specific responses indicated that GPI-0100, <bold>10</bold>, and <bold>11</bold> potentiated mixed Th1 and Th2 antigen-specific responses, whereas <bold>12</bold> mainly enhanced Th2 responses. Taken together, the results demonstrated that QS-21 analogs <bold>10</bold> and <bold>11</bold> were comparable to GPI-0100 in potentiating systemic antigen-specific responses. The results confirmed that derivatization at the glucuronic acid unit attached to C3 of the triterpenoid core could be a viable way to access chemically stable new saponin adjuvants, as suggested by the early SAR studies of Kensil et al. [<xref rid="B88-vaccines-09-00222" ref-type="bibr">88</xref>] and the preclinical success of GPI-0100. It is a practical and cost-effective strategy for preparing a large number of saponin adjuvants for property screenings and large-scale production [<xref rid="B115-vaccines-09-00222" ref-type="bibr">115</xref>,<xref rid="B116-vaccines-09-00222" ref-type="bibr">116</xref>,<xref rid="B117-vaccines-09-00222" ref-type="bibr">117</xref>]. The results also clearly showed that the structure of the incorporated side chain had a significant impact on adjuvant activity in terms of the magnitude and nature of the responses [<xref rid="B116-vaccines-09-00222" ref-type="bibr">116</xref>].</p><p>Wang et al. also synthesized QS-17/18 analogs, e.g., <bold>13</bold>&#8211;<bold>16</bold> (<xref ref-type="fig" rid="vaccines-09-00222-f005">Figure 5</xref>) [<xref rid="B117-vaccines-09-00222" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-09-00222" ref-type="bibr">118</xref>]. Analogs <bold>14</bold> does not have the natural acyl side chain at the original position, instead it has a plain aliphatic side chain on the other side of the molecule. By using the same immunological evaluation procedure for QS-21 analogs <bold>9</bold>&#8211;<bold>12</bold>, the results showed that analog <bold>13</bold> without a side chain had a significantly different adjuvant activity profile from that of <bold>14</bold>, especially in boosting IgG2a responses. Saponin <bold>13</bold> only stimulated a Th2 immune response, while analog <bold>14</bold> had an adjuvant activity profile similar to that of GPI-0100 and thus might potentiate a mixed Th1 and Th2 immunity [<xref rid="B118-vaccines-09-00222" ref-type="bibr">118</xref>]. Saponin <bold>15</bold> stimulated a more Th2-skewed immunity, and <bold>16</bold> stimulated a more Th1-skewed immunity than other QS-17 analogs [<xref rid="B117-vaccines-09-00222" ref-type="bibr">117</xref>,<xref rid="B119-vaccines-09-00222" ref-type="bibr">119</xref>].</p><p>Wang et al. noticed the strikingly structural resemblance between the de-acylated QS-17/18 (<bold>13</bold>) and <italic toggle="yes">Momordica</italic> saponins (<italic toggle="yes">MS</italic>) I and II (<bold>17</bold> and <bold>18</bold>, <xref ref-type="fig" rid="vaccines-09-00222-f006">Figure 6</xref>). These two saponins were isolated from the seeds of <italic toggle="yes">Momordica cochinchinensis</italic> SPRENG (MC), a perennial vine with readily available seeds [<xref rid="B120-vaccines-09-00222" ref-type="bibr">120</xref>]. Their structures only differ in the triterpenoid core, i.e., <italic toggle="yes">MS</italic> I (<bold>17</bold>) has a gypsogenin core (R<sub>3</sub> = H, <xref ref-type="fig" rid="vaccines-09-00222-f006">Figure 6</xref>) while <italic toggle="yes">MS</italic> II (<bold>18</bold>) has a quillaic acid core (R<sub>3</sub> = OH, <xref ref-type="fig" rid="vaccines-09-00222-f006">Figure 6</xref>), identical to the core of QS-21 and QS-17/18. Based on the different adjuvant properties observed in saponins <bold>13</bold> and <bold>14</bold>, it was inferred that incorporating the same plain side chain of <bold>14</bold> to <italic toggle="yes">MS</italic> I/II might lead to new adjuvants with similar adjuvant activity to <bold>14</bold> due to their structural resemblance. Thus, saponins <bold>19</bold> and <bold>20</bold> were readily synthesized in one step as depicted in <xref ref-type="fig" rid="vaccines-09-00222-f006">Figure 6</xref>.</p><p>Indeed, the new derivatives, <bold>19</bold> and <bold>20</bold>, showed significantly improved adjuvant activity in terms of antigen-specific IgG secretion when compared with the natural <italic toggle="yes">Momordica</italic> saponins (<xref ref-type="fig" rid="vaccines-09-00222-f007">Figure 7</xref>). It was expected that the derivative of <italic toggle="yes">MS</italic> II should resemble the adjuvant property of <bold>14</bold> more than that of <italic toggle="yes">MS</italic> I in that both <italic toggle="yes">MS</italic> II and <italic toggle="yes">QS</italic> derivatives have the same quillaic acid triterpene core while <italic toggle="yes">MS</italic> I has a gypsogenin core. Interestingly, it was the derivative of <italic toggle="yes">MS</italic> I, i.e., <bold>19</bold> (named VSA-1), showed an IgG2a/IgG1 ratio similar to that of <bold>14</bold> and the positive control GPI-0100 (<xref ref-type="fig" rid="vaccines-09-00222-f007">Figure 7</xref>). Wang et al. went on to confirm that in the <italic toggle="yes">MS</italic> series of derivatives, the structure of the incorporated side chain has a significant impact on adjuvanticity [<xref rid="B119-vaccines-09-00222" ref-type="bibr">119</xref>], as seen in the QS series of derivatives [<xref rid="B95-vaccines-09-00222" ref-type="bibr">95</xref>,<xref rid="B116-vaccines-09-00222" ref-type="bibr">116</xref>,<xref rid="B119-vaccines-09-00222" ref-type="bibr">119</xref>].</p><p>Among the studied <italic toggle="yes">MS</italic> derivatives, VSA-2 (<bold>21</bold>, <xref ref-type="fig" rid="vaccines-09-00222-f008">Figure 8</xref>), a derivative of <italic toggle="yes">MS</italic> II through incorporating11-aminoundecanoic acid benzyl ester as side chain, showed a consistently higher IgG2a/IgG1 ratio than that of GPI-0100 [<xref rid="B119-vaccines-09-00222" ref-type="bibr">119</xref>] and QS-21 (unpublished results). Interestingly, with this same side chain, the <italic toggle="yes">MS</italic> I and <italic toggle="yes">MS</italic> II derivatives demonstrated dramatically different adjuvant activities; the <italic toggle="yes">MS</italic> I derivative showed much lower IgG2a titers than both <bold>19</bold> (VSA-1) and <bold>21</bold> (VSA-2) with similar overall IgG titers. Again, these results suggest that a saponin&#8217;s adjuvant property is probably determined by its specific molecular structure (including the side chain structure), not by its overall amphipathicity, HLB, or the presence/absence of a particular functional group.</p><p>Wang et al. recently synthesized and evaluated another series of <italic toggle="yes">QS</italic> derivatives containing saponin <bold>7</bold>, <bold>23</bold>, and <bold>24</bold> (<xref ref-type="fig" rid="vaccines-09-00222-f009">Figure 9</xref>). These three synthetic saponins are stereoisomers, with <bold>7</bold> mimic natural QS-7 and QS-21. Compared with the structure of QS-21, synthetic saponin <bold>7</bold> does not have the characteristic acyl side chain; instead, it has two acetyl groups at 3-O and 4-O of the C28 fucosyl unit. The isomeric saponin <bold>23</bold> differs from <bold>7</bold> only in the stereochemisty of the glycosidic ester bond between the tetrasaccharide and the C28 carboxyl group of quillaic acid core, with <bold>7</bold> having a beta bond as in natural QS-7 and QS-21, but <bold>23</bold> having an unnatural alpha bond. Another stereisomer, <bold>24</bold>, only differs from <bold>7</bold> in the stereochemistry of an internal glycosidic bond as indicated in <xref ref-type="fig" rid="vaccines-09-00222-f009">Figure 9</xref>. Interestingly, saponin <bold>7</bold> showed dramatically different adjuvant activity from the other two stereoisomers. Saponins <bold>23</bold> and <bold>24</bold> completely lost their capacity in enhancing antigen-specific IgGs, while saponin <bold>7</bold> remained highly active as an immunostimulant [<xref rid="B112-vaccines-09-00222" ref-type="bibr">112</xref>]. The observed loss of adjuvanticity due to the unnatural glycosidic ester bond between the tetrasaccharide domain and quillaic acid core is consistent with recent results of Ragupathi and Tan et al. in the study of their synthetic <italic toggle="yes">QS</italic> analogs [<xref rid="B121-vaccines-09-00222" ref-type="bibr">121</xref>]. As shown in the case of <bold>24</bold>, change of stereochemistry within the C28 oligosaccharide domain would also cost the saponin&#8217;s adjuvant activity. Moreover, changing the size of oligosaccharide [<xref rid="B112-vaccines-09-00222" ref-type="bibr">112</xref>] or replacing the original sugar units with structurally similar alternatives [<xref rid="B122-vaccines-09-00222" ref-type="bibr">122</xref>] in the synthetic analogs resulted in their significant loss of adjuvant activity. Thus, the role of the oligosaccharide is clearly not for maintaining a desirable HLB, and it is more likely for specific molecular recognition that is crucial to adjuvant activity.</p><p>Recent SAR studies not only provide mechanistic clues, suggesting saponins&#8216; adjuvant activity originated more likely from their interaction with specific molecular receptors than from their amphipathicity, but also lead to some practical alternatives to QS-21, e.g., the more accessible VSA-1 and VSA-2 adjuvants. The available toxicity data show that VSA-1&#8242;s toxicity is similar to that of GPI-0100, much less toxic than the widely used natural saponins [<xref rid="B123-vaccines-09-00222" ref-type="bibr">123</xref>]. While injected in 0.1 mL of PBS (BALB/c, female, 10 weeks of age) via the subcutaneous route, all of the mice in the groups treated with VSA-1 (2000 &#956;g) survived, and the groups with VSA-1 (5000 &#956;g) or <italic toggle="yes">Quil</italic> A (100 &#956;g) reached endpoints within five days post injection that required euthanasia. <italic toggle="yes">Quil</italic> A, a purified mixture of <italic toggle="yes">QS</italic> saponins containing QS-21, has a similar adjuvant activity to QS-21 in potentiating a mixed Th1/Th2 immunity and CTL production. The surviving mice all had healthy looking fur and appeared to be behaving normally. None of the surviving mice seemed lethargic in any way by day 7, and no lesion formation was observed on any of the mice. These data show that the acute toxicity of VSA-1 was much lower than that of <italic toggle="yes">Quil</italic> A (which has a toxicity profile similar to that of QS-21, and the recommended dose of QS-21 for mice is no more than 20 &#956;g). Recent studies showed that VSA-2 also had low toxicity (unpublished). In ongoing evaluations of VSA adjuvants in different experimental vaccines, VSA (at dose of 50 &#956;g/mice) showed better activity than the established clinical and experimental adjuvants such as QS-21, CpG+MPL, alum, and Freund&#8217;s adjuvant (unpublished).</p></sec><sec sec-type="conclusions" id="sec5-vaccines-09-00222"><title>5. Conclusions</title><p>Saponins, including QS-21, could play a multifaceted role in orchestrating an effective and sophisticated antigen-specific immune response. The amphipathicity could probably contribute to, as suggested, facilitating cholesterol-mediated immune cell uptakes and other non-receptor-mediated process. However, SAR studies indicate the unique adjuvant activity of QS-21 should be attributed more to its interaction with specific molecular targets, given significant stimulating activity profile change with subtle change of the molecular structure even when the HLB of the molecules remain largely unchanged. Given the sensitivity of the structure-dependent adjuvant activity, the mechanistic insights obtained with a saponin probe equipped with a large imaging group might not be extrapolated to QS-21 unless the probe&#8217;s adjuvant activity/toxicity profiles closely resemble that of QS-21.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Funding</title><p>This research was funded by NIH, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM120159">GM120159</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AI099407">AI099407</ext-link>.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The author has filed a patent application for VSA-1, VSA-2, and related adjuvants. The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-09-00222"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballou</surname><given-names>W.R.</given-names></name></person-group><article-title>The development of the RTS,S malaria vaccine candidate: Challenges and lessons</article-title><source>Parasite Immunol.</source><year>2009</year><volume>31</volume><fpage>492</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.2009.01143.x</pub-id><pub-id pub-id-type="pmid">19691554</pub-id></element-citation></ref><ref id="B2-vaccines-09-00222"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delrieu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ousset</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Caillaud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B.</given-names></name></person-group><article-title>&#8216;Clinical trials in Alzheimer&#8217;s disease&#8217;: Immunotherapy approaches</article-title><source>J. Neurochem.</source><year>2012</year><volume>120</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07458.x</pub-id><pub-id pub-id-type="pmid">21883222</pub-id></element-citation></ref><ref id="B3-vaccines-09-00222"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klebanoff</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Acquavella</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>Therapeutic cancer vaccines: Are we there yet?</article-title><source>Immunol. Rev.</source><year>2010</year><volume>239</volume><fpage>27</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00979.x</pub-id><pub-id pub-id-type="pmcid">PMC3075547</pub-id><pub-id pub-id-type="pmid">21198663</pub-id></element-citation></ref><ref id="B4-vaccines-09-00222"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aderem</surname><given-names>A.</given-names></name></person-group><article-title>A 2020 vision for vaccines against HIV, tuberculosis and malaria</article-title><source>Nature</source><year>2011</year><volume>473</volume><fpage>463</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/nature10124</pub-id><pub-id pub-id-type="pmid">21614073</pub-id></element-citation></ref><ref id="B5-vaccines-09-00222"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schijns</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Tejada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barjaktarovi&#263;</surname><given-names>&#381;.</given-names></name><name name-style="western"><surname>Bouzalas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brimnes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chernysh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gizurarson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gursel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jakopin</surname><given-names>&#381;.</given-names></name><name name-style="western"><surname>Lawrenz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Modulation of immune responses using adjuvants to facilitate therapeutic vaccination</article-title><source>Immunol. Rev.</source><year>2020</year><volume>296</volume><fpage>169</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1111/imr.12889</pub-id><pub-id pub-id-type="pmid">32594569</pub-id><pub-id pub-id-type="pmcid">PMC7497245</pub-id></element-citation></ref><ref id="B6-vaccines-09-00222"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jensen-Jarolim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pali-Scholl</surname><given-names>I.</given-names></name></person-group><article-title>The ABC of clinical and experimental adjuvants a brief overview</article-title><source>Immunol. Lett.</source><year>2010</year><volume>128</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2009.10.005</pub-id><pub-id pub-id-type="pmid">19895847</pub-id><pub-id pub-id-type="pmcid">PMC2999744</pub-id></element-citation></ref><ref id="B7-vaccines-09-00222"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>A.X.</given-names></name><name name-style="western"><surname>Truneh</surname><given-names>A.</given-names></name></person-group><article-title>Current vaccine adjuvants: An overview of a diverse class</article-title><source>Front. Biosci.</source><year>2004</year><volume>9</volume><fpage>2972</fpage><lpage>2988</lpage><pub-id pub-id-type="doi">10.2741/1452</pub-id><pub-id pub-id-type="pmid">15353330</pub-id></element-citation></ref><ref id="B8-vaccines-09-00222"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name></person-group><article-title>Unmet needs in modern vaccinology: Adjuvants to improve the immune response</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.07.021</pub-id><pub-id pub-id-type="pmid">20713254</pub-id></element-citation></ref><ref id="B9-vaccines-09-00222"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sharp</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name></person-group><article-title>Discovery of vaccine adjuvants</article-title><source>Development of Therapeutic Agents Handbook</source><edition>1st ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Gad</surname><given-names>S.C.</given-names></name></person-group><publisher-name>John Wiley &amp; Sons, Inc</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2012</year><fpage>533</fpage><lpage>546</lpage></element-citation></ref><ref id="B10-vaccines-09-00222"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name></person-group><article-title>Selection of adjuvants for enhanced vaccine potency</article-title><source>World J. Vaccin.</source><year>2011</year><volume>01</volume><fpage>33</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.4236/wjv.2011.12007</pub-id></element-citation></ref><ref id="B11-vaccines-09-00222"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Weeratna</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>McCluskie</surname><given-names>M.J.</given-names></name></person-group><article-title>Recent advances in vaccine adjuvants</article-title><source>Emerging Trends in Antibacterial Discovery: Answering the Call to Arms</source><person-group person-group-type="editor"><name name-style="western"><surname>Miller</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>P.F.</given-names></name></person-group><publisher-name>Caister Academic Press</publisher-name><publisher-loc>Poole, UK</publisher-loc><year>2011</year><fpage>303</fpage><lpage>322</lpage></element-citation></ref><ref id="B12-vaccines-09-00222"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Vaccine adjuvants: Putting innate immunity to work</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></element-citation></ref><ref id="B13-vaccines-09-00222"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banday</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Jeelani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hruby</surname><given-names>V.J.</given-names></name></person-group><article-title>Cancer vaccine adjuvants&#8212;recent clinical progress and future perspectives</article-title><source>Immunopharmacol. Immunotoxicol.</source><year>2015</year><volume>37</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.3109/08923973.2014.971963</pub-id><pub-id pub-id-type="pmid">25318595</pub-id></element-citation></ref><ref id="B14-vaccines-09-00222"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastola</surname><given-names>R.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Keum</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bashyal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name></person-group><article-title>Vaccine adjuvants: Smart components to boost the immune system</article-title><source>Arch. Pharm. Res.</source><year>2017</year><volume>40</volume><fpage>1238</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1007/s12272-017-0969-z</pub-id><pub-id pub-id-type="pmid">29027637</pub-id></element-citation></ref><ref id="B15-vaccines-09-00222"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Preiss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tavares Da Silva</surname><given-names>F.</given-names></name><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name></person-group><article-title>Vaccine Adjuvants: From 1920 to 2015 and Beyond</article-title><source>Vaccines</source><year>2015</year><volume>3</volume><fpage>320</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.3390/vaccines3020320</pub-id><pub-id pub-id-type="pmid">26343190</pub-id><pub-id pub-id-type="pmcid">PMC4494348</pub-id></element-citation></ref><ref id="B16-vaccines-09-00222"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temizoz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name></person-group><article-title>Vaccine adjuvants as potential cancer immunotherapeutics</article-title><source>Int. Immunol.</source><year>2016</year><volume>28</volume><fpage>329</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxw015</pub-id><pub-id pub-id-type="pmid">27006304</pub-id><pub-id pub-id-type="pmcid">PMC4922024</pub-id></element-citation></ref><ref id="B17-vaccines-09-00222"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mbow</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Valiante</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name></person-group><article-title>New adjuvants for human vaccines</article-title><source>Curr. Opin. Immunol.</source><year>2010</year><volume>22</volume><fpage>411</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2010.04.004</pub-id><pub-id pub-id-type="pmid">20466528</pub-id></element-citation></ref><ref id="B18-vaccines-09-00222"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giudice</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name></person-group><article-title>Correlates of adjuvanticity: A review on adjuvants in licensed vaccines</article-title><source>Semin. Immunol.</source><year>2018</year><volume>2018</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2018.05.001</pub-id><pub-id pub-id-type="pmid">29801750</pub-id></element-citation></ref><ref id="B19-vaccines-09-00222"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.</given-names></name></person-group><article-title>Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3167</fpage><lpage>3178</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.055</pub-id><pub-id pub-id-type="pmid">31047671</pub-id></element-citation></ref><ref id="B20-vaccines-09-00222"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Halmuthur</surname><given-names>S.K.M.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name></person-group><article-title>An overview of novel adjuvants designed for improving vaccine efficacy</article-title><source>Trends Pharmacol. Sci.</source><year>2017</year><volume>38</volume><fpage>771</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2017.06.002</pub-id><pub-id pub-id-type="pmid">28668223</pub-id></element-citation></ref><ref id="B21-vaccines-09-00222"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Friedland</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Hanon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name></person-group><article-title>Towards an evidence based approach for the development of adjuvanted vaccines</article-title><source>Curr. Opin. Immunol.</source><year>2017</year><volume>47</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.07.010</pub-id><pub-id pub-id-type="pmid">28755542</pub-id></element-citation></ref><ref id="B22-vaccines-09-00222"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>W.-F.</given-names></name></person-group><article-title>Vaccine Adjuvants</article-title><source>Understanding Modern Vaccines Perspectives in Vaccinology</source><person-group person-group-type="editor"><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>A.L.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2011</year><volume>Volume 1</volume><fpage>89</fpage><lpage>113</lpage></element-citation></ref><ref id="B23-vaccines-09-00222"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenny</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Pope</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Waddington</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>U.</given-names></name></person-group><article-title>Immunological notes. XVI1.&#8722;XXIV</article-title><source>J. Pathol. Bacteriol.</source><year>1926</year><volume>29</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/path.1700290106</pub-id></element-citation></ref><ref id="B24-vaccines-09-00222"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Alum: An old dog with new tricks</article-title><source>Emerg. Microbes Infect.</source><year>2016</year><volume>5</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/emi.2016.40</pub-id><pub-id pub-id-type="pmcid">PMC4820675</pub-id><pub-id pub-id-type="pmid">27004761</pub-id></element-citation></ref><ref id="B25-vaccines-09-00222"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>HogenEsch</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>Optimizing the utilization of aluminum adjuvants in vaccines: You might just get what you want</article-title><source>NPJ Vaccines</source><year>2018</year><volume>3</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41541-018-0089-x</pub-id><pub-id pub-id-type="pmid">30323958</pub-id><pub-id pub-id-type="pmcid">PMC6180056</pub-id></element-citation></ref><ref id="B26-vaccines-09-00222"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name></person-group><article-title>From discovery to licensure, the Adjuvant System story</article-title><source>Hum. Vaccin. Immunother.</source><year>2017</year><volume>13</volume><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1225635</pub-id><pub-id pub-id-type="pmid">27636098</pub-id><pub-id pub-id-type="pmcid">PMC5287309</pub-id></element-citation></ref><ref id="B27-vaccines-09-00222"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leo</surname><given-names>O.</given-names></name></person-group><article-title>Innate Immunity and Vaccine Adjuvants: From Concepts to the Development of a Unique Adjuvant System AS04 Used for the Formulation of a Human Papillomavirus (HPV) Vaccine</article-title><source>Curr. Cancer Ther. Rev.</source><year>2010</year><volume>6</volume><fpage>126</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.2174/157339410791202574</pub-id></element-citation></ref><ref id="B28-vaccines-09-00222"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Most</surname><given-names>R.v.d.</given-names></name><name name-style="western"><surname>Bauchau</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bekkat-Berkani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Schuind</surname><given-names>A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>F.T.D.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name><name name-style="western"><surname>Innis</surname><given-names>B.L.</given-names></name></person-group><article-title>Safety of AS03-adjuvanted influenza vaccines: A review of the evidence</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3006</fpage><lpage>3021</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.048</pub-id><pub-id pub-id-type="pmid">31031030</pub-id></element-citation></ref><ref id="B29-vaccines-09-00222"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkins</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Kazmin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Napolitani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Clutterbuck</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Siegrist</surname><given-names>C.-A.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>A.J.</given-names></name></person-group><article-title>AS03- and MF59-Adjuvanted influenza vaccines in Children</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1760</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01760</pub-id><pub-id pub-id-type="pmid">29326687</pub-id><pub-id pub-id-type="pmcid">PMC5733358</pub-id></element-citation></ref><ref id="B30-vaccines-09-00222"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Ottc</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Gregorio</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>A.</given-names></name></person-group><article-title>The mechanism of action of MF59&#8212;An innately attractive adjuvant formulation</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>4341</fpage><lpage>4348</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.061</pub-id><pub-id pub-id-type="pmid">22682289</pub-id></element-citation></ref><ref id="B31-vaccines-09-00222"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheiermann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name></person-group><article-title>Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>6377</fpage><lpage>6389</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.065</pub-id><pub-id pub-id-type="pmid">24975812</pub-id><pub-id pub-id-type="pmcid">PMC4252359</pub-id></element-citation></ref><ref id="B32-vaccines-09-00222"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bode</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Steinhagen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kinjo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name></person-group><article-title>CpG DNA as a vaccine adjuvant</article-title><source>Expert Rev. Vaccines</source><year>2011</year><volume>10</volume><fpage>499</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1586/erv.10.174</pub-id><pub-id pub-id-type="pmid">21506647</pub-id><pub-id pub-id-type="pmcid">PMC3108434</pub-id></element-citation></ref><ref id="B33-vaccines-09-00222"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Laupeze</surname><given-names>B.</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hergli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name></person-group><article-title>Adjuvant system AS01: Helping to overcome the challenges of modern vaccines</article-title><source>Expert Rev. Vaccines</source><year>2017</year><volume>16</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1080/14760584.2016.1213632</pub-id><pub-id pub-id-type="pmid">27448771</pub-id></element-citation></ref><ref id="B34-vaccines-09-00222"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Chahine</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Sucher</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>C.</given-names></name></person-group><article-title>Shingrix: The new adjuvanted recombinant herpes zoster vaccine</article-title><source>Ann. Pharmacother.</source><year>2018</year><volume>52</volume><fpage>673</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1177/1060028018758431</pub-id><pub-id pub-id-type="pmid">29457489</pub-id></element-citation></ref><ref id="B35-vaccines-09-00222"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacaille-Dubois</surname><given-names>M.A.</given-names></name></person-group><article-title>Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review</article-title><source>Phytomedicine</source><year>2019</year><volume>60</volume><fpage>152905</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2019.152905</pub-id><pub-id pub-id-type="pmid">31182297</pub-id><pub-id pub-id-type="pmcid">PMC7127804</pub-id></element-citation></ref><ref id="B36-vaccines-09-00222"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Van Mechelen</surname><given-names>M.</given-names></name></person-group><article-title>Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems</article-title><source>Expert Rev. Vaccines</source><year>2011</year><volume>10</volume><fpage>471</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1586/erv.11.29</pub-id><pub-id pub-id-type="pmid">21506645</pub-id></element-citation></ref><ref id="B37-vaccines-09-00222"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name></person-group><article-title>Saponins as vaccine adjuvants</article-title><source>Crit. Rev. Ther. Drug Carrier Syst.</source><year>1996</year><volume>13</volume><fpage>1</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">8853958</pub-id></element-citation></ref><ref id="B38-vaccines-09-00222"><label>38.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Storey</surname><given-names>J.</given-names></name></person-group><article-title>Effects of QS-21 on Innate and Adaptive Immune Responses</article-title><source>Vaccine Adjuvants: Immunological and Clinical Principles</source><person-group person-group-type="editor"><name name-style="western"><surname>Hackett</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Harn</surname><given-names>D.A.J.</given-names></name></person-group><publisher-name>Humana Press Inc.</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2005</year><fpage>221</fpage><lpage>234</lpage></element-citation></ref><ref id="B39-vaccines-09-00222"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>U.</given-names></name><name name-style="western"><surname>Lennick</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marciani</surname><given-names>D.</given-names></name></person-group><article-title>Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex</article-title><source>J. Immun.</source><year>1991</year><volume>146</volume><fpage>431</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">1987271</pub-id></element-citation></ref><ref id="B40-vaccines-09-00222"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Munroe</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Leombruno</surname><given-names>D.</given-names></name><name name-style="western"><surname>Recchia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Coughlin</surname><given-names>R.T.</given-names></name></person-group><article-title>Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses</article-title><source>J. Immun.</source><year>1992</year><volume>148</volume><fpage>2357</fpage><lpage>2362</lpage><pub-id pub-id-type="pmid">1373166</pub-id></element-citation></ref><ref id="B41-vaccines-09-00222"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Navarro-Villalobos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rohde</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Synthesis of the potent immunostimulatory adjuvant QS-21A</article-title><source>J. Am. Chem. Soc.</source><year>2005</year><volume>127</volume><fpage>3256</fpage><lpage>3257</lpage><pub-id pub-id-type="doi">10.1021/ja0422007</pub-id><pub-id pub-id-type="pmid">15755124</pub-id></element-citation></ref><ref id="B42-vaccines-09-00222"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Damani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Ragupathi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Synthesis of QS-21-xylose: Establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine</article-title><source>Angew. Chem.</source><year>2008</year><volume>47</volume><fpage>6395</fpage><lpage>6398</lpage><pub-id pub-id-type="doi">10.1002/anie.200801885</pub-id><pub-id pub-id-type="pmid">18624313</pub-id><pub-id pub-id-type="pmcid">PMC2602848</pub-id></element-citation></ref><ref id="B43-vaccines-09-00222"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cleland</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Basa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Spellman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>M.F.</given-names></name></person-group><article-title>Isomerization and Formulation Stability of the Vaccine Adjuvant QS-21</article-title><source>J. Pharm. Sci.</source><year>1996</year><volume>85</volume><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1021/js9503136</pub-id><pub-id pub-id-type="pmid">8926578</pub-id></element-citation></ref><ref id="B44-vaccines-09-00222"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Geyter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Swevers</surname><given-names>L.</given-names></name><name name-style="western"><surname>Soin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Geelen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smagghe</surname><given-names>G.</given-names></name></person-group><article-title>Saponins do not affect the ecdysteroid receptor complex but cause membrane permeation in insect culture cell lines</article-title><source>J. Insect. Physiol.</source><year>2012</year><volume>58</volume><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.jinsphys.2011.09.005</pub-id><pub-id pub-id-type="pmid">22057058</pub-id></element-citation></ref><ref id="B45-vaccines-09-00222"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorent</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Quetin-Leclercq</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mingeot-Leclercq</surname><given-names>M.-P.</given-names></name></person-group><article-title>The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells</article-title><source>Org. Biomol. Chem.</source><year>2014</year><volume>12</volume><fpage>8803</fpage><lpage>8822</lpage><pub-id pub-id-type="doi">10.1039/C4OB01652A</pub-id><pub-id pub-id-type="pmid">25295776</pub-id></element-citation></ref><ref id="B46-vaccines-09-00222"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ohgitani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>M.</given-names></name></person-group><article-title>Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants</article-title><source>Biol. Chem.</source><year>2000</year><volume>381</volume><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1515/BC.2000.009</pub-id><pub-id pub-id-type="pmid">10722052</pub-id></element-citation></ref><ref id="B47-vaccines-09-00222"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#246;ttger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Melzig</surname><given-names>M.F.</given-names></name></person-group><article-title>The influence of saponins on cell membrane cholesterol</article-title><source>Bioorg. Med. Chem.</source><year>2013</year><volume>21</volume><fpage>7118</fpage><lpage>7124</lpage><pub-id pub-id-type="pmid">24084294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmc.2013.09.008</pub-id></element-citation></ref><ref id="B48-vaccines-09-00222"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baz Morelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Becher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Koernig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Drane</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maraskovsky</surname><given-names>E.</given-names></name></person-group><article-title>ISCOMATRIX: A novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases</article-title><source>J. Med. Microbiol.</source><year>2012</year><volume>61</volume><fpage>935</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.040857-0</pub-id><pub-id pub-id-type="pmid">22442293</pub-id></element-citation></ref><ref id="B49-vaccines-09-00222"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearse</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Drane</surname><given-names>D.</given-names></name></person-group><article-title>ISCOMATRIX adjuvant for antigen delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2005</year><volume>57</volume><fpage>465</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2004.09.006</pub-id><pub-id pub-id-type="pmid">15560952</pub-id></element-citation></ref><ref id="B50-vaccines-09-00222"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.P.</given-names></name></person-group><article-title>ISCOMs and ISCOMATRIX</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>4388</fpage><lpage>4401</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.032</pub-id><pub-id pub-id-type="pmid">19450632</pub-id></element-citation></ref><ref id="B51-vaccines-09-00222"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Koster</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>D.J.</given-names></name></person-group><article-title>Membrane cholesterol is essential for triterpenoid saponin augmentation of a saporin-based immunotoxin directed against CD19 on human lymphoma cells</article-title><source>Biochim. Biophys. Acta. Biomembr.</source><year>2017</year><volume>1859</volume><fpage>993</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2017.02.013</pub-id><pub-id pub-id-type="pmid">28235471</pub-id></element-citation></ref><ref id="B52-vaccines-09-00222"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bangham</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Horne</surname><given-names>R.W.</given-names></name></person-group><article-title>Action of saponin on biological cell membranes</article-title><source>Nature</source><year>1962</year><volume>196</volume><fpage>952</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1038/196952a0</pub-id><pub-id pub-id-type="pmid">13966357</pub-id></element-citation></ref><ref id="B53-vaccines-09-00222"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korchowiec</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gorczyca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wojszko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Janikowska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rogalska</surname><given-names>E.</given-names></name></person-group><article-title>Impact of two different saponins on the organization of model lipid membranes</article-title><source>Biochim. Biophys. Acta.</source><year>2015</year><volume>1848</volume><fpage>1963</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2015.06.007</pub-id><pub-id pub-id-type="pmid">26055895</pub-id></element-citation></ref><ref id="B54-vaccines-09-00222"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ohgitani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>M.</given-names></name></person-group><article-title>Relationship between adjuvant activity and amphipathic structure of soyasaponins</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>2145</fpage><lpage>2151</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00739-9</pub-id><pub-id pub-id-type="pmid">12706705</pub-id></element-citation></ref><ref id="B55-vaccines-09-00222"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pillion</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Amsden</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Recchia</surname><given-names>J.</given-names></name></person-group><article-title>Structure-function relationship among Quillaja saponins serving as excipients for nasal and ocular delivery of insulin</article-title><source>J. Pharm. Sci.</source><year>1996</year><volume>85</volume><fpage>518</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1021/js9504651</pub-id><pub-id pub-id-type="pmid">8742944</pub-id></element-citation></ref><ref id="B56-vaccines-09-00222"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Beltz</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Cronier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aubert</surname><given-names>A.</given-names></name></person-group><article-title>Genetically-engineered subunit vaccine against feline leukaemia virus: Protective immune response in cats</article-title><source>Vaccine</source><year>1991</year><volume>9</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(91)90262-5</pub-id><pub-id pub-id-type="pmid">1647576</pub-id></element-citation></ref><ref id="B57-vaccines-09-00222"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Amsden</surname><given-names>J.</given-names></name></person-group><article-title>QS-21 and QS-7: Purified saponin adjuvants</article-title><source>Dev. Biol. Stand.</source><year>1998</year><volume>92</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">9554258</pub-id></element-citation></ref><ref id="B58-vaccines-09-00222"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Synthesis and structure verification of the vaccine adjuvant QS-7-api. Synthetic access to homogeneous Quillaja saponaria immunostimulants</article-title><source>J. Am. Chem. Soc.</source><year>2008</year><volume>130</volume><fpage>5860</fpage><lpage>5861</lpage><pub-id pub-id-type="doi">10.1021/ja801008m</pub-id><pub-id pub-id-type="pmid">18410100</pub-id><pub-id pub-id-type="pmcid">PMC2610460</pub-id></element-citation></ref><ref id="B59-vaccines-09-00222"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scaltreto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barbon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name></person-group><article-title>QS-21 structure/function studies: Effect of acylation on adjuvant activity</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>2808</fpage><lpage>2815</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00209-8</pub-id><pub-id pub-id-type="pmid">12034108</pub-id></element-citation></ref><ref id="B60-vaccines-09-00222"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bourguignon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fierens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fochesato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dendouga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Langlet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Malissen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>B.N.</given-names></name><etal/></person-group><article-title>Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells</article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>1920</fpage><lpage>1930</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400948</pub-id><pub-id pub-id-type="pmid">25024381</pub-id></element-citation></ref><ref id="B61-vaccines-09-00222"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genito</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Phares</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Kalle</surname><given-names>F.</given-names></name><name name-style="western"><surname>Limbach</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Stefaniak</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Bergmann-Leitner</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Matyas</surname><given-names>G.R.</given-names></name><etal/></person-group><article-title>Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>3865</fpage><lpage>3874</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.070</pub-id><pub-id pub-id-type="pmid">28596090</pub-id></element-citation></ref><ref id="B62-vaccines-09-00222"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ragupathi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cappello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>P.O.</given-names></name></person-group><article-title>Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1&#177;KLH and GD3-KLH conjugates</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>530</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00195-X</pub-id><pub-id pub-id-type="pmid">11027818</pub-id></element-citation></ref><ref id="B63-vaccines-09-00222"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Van Belle</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vandepapeliere</surname><given-names>P.</given-names></name><name name-style="western"><surname>Horsmans</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carletti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wettendorff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Mechelen</surname><given-names>M.</given-names></name></person-group><article-title>Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>1084</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.10.078</pub-id><pub-id pub-id-type="pmid">25444781</pub-id></element-citation></ref><ref id="B64-vaccines-09-00222"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandepapeliere</surname><given-names>P.</given-names></name><name name-style="western"><surname>Horsmans</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van Mechelen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koutsoukos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Belle</surname><given-names>P.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hanon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wettendorff</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>1375</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.12.038</pub-id><pub-id pub-id-type="pmid">18272264</pub-id></element-citation></ref><ref id="B65-vaccines-09-00222"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agnandji</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Lell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Soulanoudjingar</surname><given-names>S.S.</given-names></name></person-group><article-title>First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>365</volume><fpage>1863</fpage><lpage>1875</lpage><pub-id pub-id-type="pmid">22007715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1102287</pub-id></element-citation></ref><ref id="B66-vaccines-09-00222"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polhemus</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Magill</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Lanar</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soisson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Diggs</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>Phase I Dose Escalation Safety and Immunogenicity Trial of Plasmodium Falciparum Apical Membrane Protein (AMA-1) FMP2.1, Adjuvanted with AS02A, in Malaria-Naive Adults at the Walter Reed Army Institute of Research</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>4203</fpage><lpage>4212</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.03.012</pub-id><pub-id pub-id-type="pmid">17442466</pub-id></element-citation></ref><ref id="B67-vaccines-09-00222"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tielemans</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Vlasak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kosa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Billiouw</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Verpooten</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Mezei</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ryba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peeters</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Mat</surname><given-names>O.</given-names></name><name name-style="western"><surname>Jadoul</surname><given-names>M.Y.</given-names></name><etal/></person-group><article-title>Immunogenicity and Safety of an Investigational AS02v-Djuvanted Hepatitis B Vaccine in Patients with Renal Insufficiency Who Failed to Respond or to Maintain Antibody Levels after Prior Vaccination: Results of Two Open, Randomized, Comparative Trials</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>1159</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.12.009</pub-id><pub-id pub-id-type="pmid">21167859</pub-id></element-citation></ref><ref id="B68-vaccines-09-00222"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Ware</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Burge</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Pre-Clinical Evaluation of New Adjuvant Formulations to Improve the Immunogenicity of the Malaria Vaccine RTS,S/AS02A</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>6483</fpage><lpage>6492</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.033</pub-id><pub-id pub-id-type="pmid">16904798</pub-id></element-citation></ref><ref id="B69-vaccines-09-00222"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandepapeliere</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rehermann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Koutsoukos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wettendorff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name></person-group><article-title>Potent Enhancement of Cellular and Humoral Immune Responses against Recombinant Hepatitis B Antigens Using AS02A Adjuvant in Healthy Adults</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>2591</fpage><lpage>2601</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.034</pub-id><pub-id pub-id-type="pmid">15780441</pub-id></element-citation></ref><ref id="B70-vaccines-09-00222"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Devaster</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Verlant</surname><given-names>V.</given-names></name><name name-style="western"><surname>Henckaerts</surname><given-names>I.</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hermand</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van Belle</surname><given-names>P.</given-names></name><name name-style="western"><surname>Poolman</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Vandepapeliere</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.10.052</pub-id><pub-id pub-id-type="pmid">24176494</pub-id></element-citation></ref><ref id="B71-vaccines-09-00222"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.F.</given-names></name></person-group><article-title>Mechanisms and pathways of innate immune activation and regulation in health and cancer</article-title><source>Hum. Vaccin Immunother.</source><year>2014</year><volume>10</volume><fpage>3270</fpage><lpage>3285</lpage><pub-id pub-id-type="doi">10.4161/21645515.2014.979640</pub-id><pub-id pub-id-type="pmid">25625930</pub-id><pub-id pub-id-type="pmcid">PMC4514086</pub-id></element-citation></ref><ref id="B72-vaccines-09-00222"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awate</surname><given-names>S.</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Mutwiri</surname><given-names>G.</given-names></name></person-group><article-title>Mechanisms of action of adjuvants</article-title><source>Front. Immunol.</source><year>2013</year><volume>4</volume><fpage>114</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00114</pub-id><pub-id pub-id-type="pmid">23720661</pub-id><pub-id pub-id-type="pmcid">PMC3655441</pub-id></element-citation></ref><ref id="B73-vaccines-09-00222"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reimer</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Lovgren-Bengtsson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Magnusson</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Fuentes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stertman</surname><given-names>L.</given-names></name></person-group><article-title>Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e41451</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0041451</pub-id><pub-id pub-id-type="pmid">22844480</pub-id><pub-id pub-id-type="pmcid">PMC3402407</pub-id></element-citation></ref><ref id="B74-vaccines-09-00222"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lovgren Bengtsson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.</given-names></name></person-group><article-title>ISCOM technologybased Matrix-M adjuvant: Success in future vaccines relies on formulation</article-title><source>Expert Rev. Vaccines</source><year>2011</year><volume>10</volume><fpage>401</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1586/erv.11.25</pub-id><pub-id pub-id-type="pmid">21506635</pub-id></element-citation></ref><ref id="B75-vaccines-09-00222"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magnusson</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Altenburg</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Bengtsson</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Bosman</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Stertman</surname><given-names>L.</given-names></name></person-group><article-title>Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice</article-title><source>Immunol. Res.</source><year>2018</year><volume>66</volume><fpage>224</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1007/s12026-018-8991-x</pub-id><pub-id pub-id-type="pmid">29594879</pub-id><pub-id pub-id-type="pmcid">PMC5899102</pub-id></element-citation></ref><ref id="B76-vaccines-09-00222"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Tejada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chea</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>George</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pillarsetty</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Ragupathi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Development of a Minimal Saponin Vaccine Adjuvant based on QS-21</article-title><source>Nat. Chem.</source><year>2014</year><volume>6</volume><fpage>635</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1038/nchem.1963</pub-id><pub-id pub-id-type="pmid">24950335</pub-id><pub-id pub-id-type="pmcid">PMC4215704</pub-id></element-citation></ref><ref id="B77-vaccines-09-00222"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Kushner</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Pozzi</surname><given-names>L.-A.M.</given-names></name><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Cloutier</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Coughlin</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>M.J.</given-names></name></person-group><article-title>Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes</article-title><source>Cell. Immunol.</source><year>1994</year><volume>154</volume><fpage>393</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1006/cimm.1994.1086</pub-id><pub-id pub-id-type="pmid">7907530</pub-id></element-citation></ref><ref id="B78-vaccines-09-00222"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Detienne</surname><given-names>S.</given-names></name><name name-style="western"><surname>Welsby</surname><given-names>I.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Coccia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Maele</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Swertvaegher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Detavernier</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Central Role of CD169(+) Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>39475</fpage><pub-id pub-id-type="doi">10.1038/srep39475</pub-id><pub-id pub-id-type="pmid">27996000</pub-id><pub-id pub-id-type="pmcid">PMC5172233</pub-id></element-citation></ref><ref id="B79-vaccines-09-00222"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pink</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kieny</surname><given-names>M.-P.</given-names></name></person-group><article-title>4th Meeting on novel adjuvants currently in/close to human clinical testing</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>2097</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.01.021</pub-id><pub-id pub-id-type="pmid">15212010</pub-id></element-citation></ref><ref id="B80-vaccines-09-00222"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D.</given-names></name></person-group><article-title>Elucidating the Mechanisms of Action of Saponin-Derived Adjuvants</article-title><source>Trends Pharmacol. Sci.</source><year>2018</year><volume>39</volume><fpage>573</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.03.005</pub-id><pub-id pub-id-type="pmid">29655658</pub-id></element-citation></ref><ref id="B81-vaccines-09-00222"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welsby</surname><given-names>I.</given-names></name><name name-style="western"><surname>Detienne</surname><given-names>S.</given-names></name><name name-style="western"><surname>N&#8217;Kuli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bechtold</surname><given-names>V.</given-names></name><name name-style="western"><surname>De Wit</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gineste</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reinheckel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Elouahabi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21</article-title><source>Front. Immunol.</source><year>2016</year><volume>7</volume><fpage>663</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00663</pub-id><pub-id pub-id-type="pmid">28105029</pub-id><pub-id pub-id-type="pmcid">PMC5215313</pub-id></element-citation></ref><ref id="B82-vaccines-09-00222"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Den Brok</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Nierkens</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wagenaars</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ruers</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Schrier</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Rijke</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Adema</surname><given-names>G.J.</given-names></name></person-group><article-title>Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>737</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.11.080</pub-id><pub-id pub-id-type="pmid">22138178</pub-id></element-citation></ref><ref id="B83-vaccines-09-00222"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Den Brok</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Bull</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wassink</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Graaf</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Wagenaars</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Minderman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amigorena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rijke</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Schrier</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>13324</fpage><pub-id pub-id-type="doi">10.1038/ncomms13324</pub-id><pub-id pub-id-type="pmid">27819292</pub-id><pub-id pub-id-type="pmcid">PMC5103066</pub-id></element-citation></ref><ref id="B84-vaccines-09-00222"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Garanina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rizvanov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khaiboullina</surname><given-names>S.</given-names></name></person-group><article-title>Inflammasomes as Targets for Adjuvants</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>252</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9040252</pub-id><pub-id pub-id-type="pmcid">PMC7238254</pub-id><pub-id pub-id-type="pmid">32235526</pub-id></element-citation></ref><ref id="B85-vaccines-09-00222"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marty-Roix</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vladimer</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Pouliot</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Buglione-Corbett</surname><given-names>R.</given-names></name><name name-style="western"><surname>West</surname><given-names>K.</given-names></name><name name-style="western"><surname>MacMicking</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Chee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants</article-title><source>J. Biol. Chem.</source><year>2016</year><volume>291</volume><fpage>1123</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.683011</pub-id><pub-id pub-id-type="pmid">26555265</pub-id><pub-id pub-id-type="pmcid">PMC4714196</pub-id></element-citation></ref><ref id="B86-vaccines-09-00222"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Duewell</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Marsters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koernig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maraskovsky</surname><given-names>E.</given-names></name><name name-style="western"><surname>Morelli</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Schnurr</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Inflammasome-Dependent and -Independent IL-18 Production Mediates Immunity to the ISCOMATRIX Adjuvant</article-title><source>J. Immun.</source><year>2014</year><volume>192</volume><fpage>3259</fpage><lpage>3268</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302011</pub-id><pub-id pub-id-type="pmid">24610009</pub-id></element-citation></ref><ref id="B87-vaccines-09-00222"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D.</given-names></name></person-group><article-title>Vaccine adjuvants: Role and mechanisms of action in vaccine immunogenicity</article-title><source>Drug Discov. Today</source><year>2003</year><volume>8</volume><fpage>934</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1016/S1359-6446(03)02864-2</pub-id><pub-id pub-id-type="pmid">14554157</pub-id></element-citation></ref><ref id="B88-vaccines-09-00222"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soltysik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Recchia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Coughlin</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name></person-group><article-title>Structure/function studies of QS-21 adjuvant: Assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function</article-title><source>Vaccine</source><year>1995</year><volume>13</volume><fpage>1403</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(95)00077-E</pub-id><pub-id pub-id-type="pmid">8578817</pub-id></element-citation></ref><ref id="B89-vaccines-09-00222"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhodes</surname><given-names>J.</given-names></name></person-group><article-title>Covalent chemical events in immune induction: Fundamental and therapeutic aspects</article-title><source>Immunol. Today</source><year>1996</year><volume>17</volume><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1016/0167-5699(96)10050-5</pub-id><pub-id pub-id-type="pmid">8854563</pub-id></element-citation></ref><ref id="B90-vaccines-09-00222"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pifferi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fuentes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tejada</surname><given-names>A.F.</given-names></name></person-group><article-title>Natural and synthetic carbohydratebased vaccine adjuvants and their mechanisms of action</article-title><source>Nat. Rev. Chem.</source><year>2021</year><volume>5</volume><fpage>197</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/s41570-020-00244-3</pub-id><pub-id pub-id-type="pmcid">PMC7829660</pub-id><pub-id pub-id-type="pmid">33521324</pub-id></element-citation></ref><ref id="B91-vaccines-09-00222"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamstrup</surname><given-names>S.</given-names></name><name name-style="western"><surname>San Martin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Doberti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grande</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dalsgaard</surname><given-names>K.</given-names></name></person-group><article-title>Preparation and characterisation of Quillaja saponin with less heterogeneity than Quil-A</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>2244</fpage><lpage>2249</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00560-5</pub-id><pub-id pub-id-type="pmid">10717344</pub-id></element-citation></ref><ref id="B92-vaccines-09-00222"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Briones</surname><given-names>R.</given-names></name></person-group><article-title>Industrial uses and sustainable supply of Quillaja Saponaria (Rosaceae) Saponins</article-title><source>Econ. Bot.</source><year>1999</year><volume>53</volume><fpage>302</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1007/BF02866642</pub-id></element-citation></ref><ref id="B93-vaccines-09-00222"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ragupathi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer</article-title><source>Expert Rev. Vaccines</source><year>2011</year><volume>10</volume><fpage>463</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">21506644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.11.18</pub-id><pub-id pub-id-type="pmcid">PMC3658151</pub-id></element-citation></ref><ref id="B94-vaccines-09-00222"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Damani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perl</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Won</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Ragupathi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Design and synthesis of potent Quillaja saponin vaccine adjuvants</article-title><source>J. Am. Chem. Soc.</source><year>2010</year><volume>132</volume><fpage>1939</fpage><lpage>1945</lpage><pub-id pub-id-type="doi">10.1021/ja9082842</pub-id><pub-id pub-id-type="pmid">20088518</pub-id><pub-id pub-id-type="pmcid">PMC2820154</pub-id></element-citation></ref><ref id="B95-vaccines-09-00222"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Tejada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis</article-title><source>Acc. Chem. Res.</source><year>2016</year><volume>49</volume><fpage>1741</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.6b00242</pub-id><pub-id pub-id-type="pmid">27568877</pub-id><pub-id pub-id-type="pmcid">PMC5032057</pub-id></element-citation></ref><ref id="B96-vaccines-09-00222"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harandi</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Medaglini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shattock</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Working Group convened by</surname><given-names>E.</given-names></name></person-group><article-title>Vaccine adjuvants: A priority for vaccine research</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>2363</fpage><lpage>2366</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.12.084</pub-id><pub-id pub-id-type="pmid">20064476</pub-id></element-citation></ref><ref id="B97-vaccines-09-00222"><label>97.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Press</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>May</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Marciani</surname><given-names>D.J.</given-names></name></person-group><article-title>Bioactive Natural Products</article-title><source>Structure/Function Relationships of Immunostimulating Saponins</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2000</year><fpage>131</fpage><lpage>174</lpage></element-citation></ref><ref id="B98-vaccines-09-00222"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacaille-Dubois</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hanquet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>Z.-H.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z.-H.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>H.</given-names></name></person-group><article-title>Acylated triterpene saponins from Silene jenisseensis</article-title><source>Phytochem.</source><year>1995</year><volume>40</volume><fpage>509</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/0031-9422(95)00222-S</pub-id><pub-id pub-id-type="pmid">7546560</pub-id></element-citation></ref><ref id="B99-vaccines-09-00222"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumazawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takimoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kawakita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nomoto</surname><given-names>K.</given-names></name></person-group><article-title>Activation of murine peritoneal macrophages by saikosaponin A, saikosaponin D and saikogenin D</article-title><source>Int. J. Immunopharmacol.</source><year>1989</year><volume>11</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/0192-0561(89)90095-7</pub-id><pub-id pub-id-type="pmid">2707937</pub-id></element-citation></ref><ref id="B100-vaccines-09-00222"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Press</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gundy</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Koratich</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>May</surname><given-names>R.D.</given-names></name></person-group><article-title>Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>3141</fpage><lpage>3151</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00118-3</pub-id><pub-id pub-id-type="pmid">10856794</pub-id></element-citation></ref><ref id="B101-vaccines-09-00222"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>L.</given-names></name><name name-style="western"><surname>May</surname><given-names>R.D.</given-names></name></person-group><article-title>Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins</article-title><source>Inter. Immunopharmacol.</source><year>2001</year><volume>1</volume><fpage>813</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1016/S1567-5769(01)00016-9</pub-id><pub-id pub-id-type="pmid">11357894</pub-id></element-citation></ref><ref id="B102-vaccines-09-00222"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Ptak</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Chamblin</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Scholl</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>May</surname><given-names>R.D.</given-names></name></person-group><article-title>Degradation of Quillaja saponaria Molina saponins: Loss of the protective effects of a herpes simplex virus 1 subunit vaccine</article-title><source>Inter. Immunopharmacol.</source><year>2002</year><volume>2</volume><fpage>1703</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1016/S1567-5769(02)00192-3</pub-id><pub-id pub-id-type="pmid">12469944</pub-id></element-citation></ref><ref id="B103-vaccines-09-00222"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Finley-Woodman</surname><given-names>K.</given-names></name><name name-style="western"><surname>May</surname><given-names>R.D.</given-names></name></person-group><article-title>Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>3961</fpage><lpage>3971</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00298-6</pub-id><pub-id pub-id-type="pmid">12922132</pub-id></element-citation></ref><ref id="B104-vaccines-09-00222"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D.</given-names></name></person-group><article-title>Is fucose the answer to the immunomodulatory paradox of Quillaja saponins?</article-title><source>Inter. Immunopharmacol.</source><year>2015</year><volume>29</volume><fpage>908</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2015.10.028</pub-id><pub-id pub-id-type="pmid">26603552</pub-id></element-citation></ref><ref id="B105-vaccines-09-00222"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Bhunia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nerella</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Alvala</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mahabalarao</surname><given-names>S.K.H.</given-names></name></person-group><article-title>Novel trisaccharide based phospholipids as immunomodulators</article-title><source>Int. Immunopharmacol.</source><year>2019</year><volume>74</volume><fpage>105684</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2019.105684</pub-id><pub-id pub-id-type="pmid">31200340</pub-id></element-citation></ref><ref id="B106-vaccines-09-00222"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Lipopolysaccharide-induced DC-SIGN/TLR4 crosstalk activates NLRP3 inflammasomes via MyD88-independent signaling in gastric epithelial cells</article-title><source>Exp. Cell Res.</source><year>2020</year><volume>396</volume><fpage>112292</fpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2020.112292</pub-id><pub-id pub-id-type="pmid">32961144</pub-id></element-citation></ref><ref id="B107-vaccines-09-00222"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Den Dunnen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gringhuis</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Geijtenbeek</surname><given-names>T.B.</given-names></name></person-group><article-title>Innate signaling by the C-type lectin DC-SIGN dictates immune responses</article-title><source>Cancer Immunol. Immunother.</source><year>2009</year><volume>58</volume><fpage>1149</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1007/s00262-008-0615-1</pub-id><pub-id pub-id-type="pmid">18998127</pub-id><pub-id pub-id-type="pmcid">PMC11030075</pub-id></element-citation></ref><ref id="B108-vaccines-09-00222"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engering</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geijtenbeek</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>van Vliet</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Wijers</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Liempt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Demaurex</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fransen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Piguet</surname><given-names>V.</given-names></name><etal/></person-group><article-title>The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells</article-title><source>J. Immunol.</source><year>2002</year><volume>168</volume><fpage>2118</fpage><lpage>2126</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.5.2118</pub-id><pub-id pub-id-type="pmid">11859097</pub-id></element-citation></ref><ref id="B109-vaccines-09-00222"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Unione</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wolfert</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Valverde</surname><given-names>P.</given-names></name><name name-style="western"><surname>Arda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jimenez-Barbero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boons</surname><given-names>G.J.</given-names></name></person-group><article-title>Mono- and Di-Fucosylated Glycans of the Parasitic Worm S. mansoni are Recognized Differently by the Innate Immune Receptor DC-SIGN</article-title><source>Chemistry</source><year>2020</year><volume>26</volume><fpage>15605</fpage><lpage>15612</lpage><pub-id pub-id-type="doi">10.1002/chem.202002619</pub-id><pub-id pub-id-type="pmid">32957164</pub-id><pub-id pub-id-type="pmcid">PMC7894523</pub-id></element-citation></ref><ref id="B110-vaccines-09-00222"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steeghs</surname><given-names>L.</given-names></name><name name-style="western"><surname>van Vliet</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Uronen-Hansson</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Mourik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Engering</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sanchez-Hernandez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>N.</given-names></name><name name-style="western"><surname>Callard</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Putten</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>van der Ley</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function</article-title><source>Cell Microbiol.</source><year>2006</year><volume>8</volume><fpage>316</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2005.00623.x</pub-id><pub-id pub-id-type="pmid">16441441</pub-id></element-citation></ref><ref id="B111-vaccines-09-00222"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svajger</surname><given-names>U.</given-names></name><name name-style="western"><surname>Anderluh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jeras</surname><given-names>M.</given-names></name><name name-style="western"><surname>Obermajer</surname><given-names>N.</given-names></name></person-group><article-title>C-type lectin DC-SIGN: An adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity</article-title><source>Cell Signal</source><year>2010</year><volume>22</volume><fpage>1397</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2010.03.018</pub-id><pub-id pub-id-type="pmid">20363321</pub-id><pub-id pub-id-type="pmcid">PMC7127357</pub-id></element-citation></ref><ref id="B112-vaccines-09-00222"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skalamera</surname><given-names>&#272;.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name></person-group><article-title>Impact of C28 Oligosaccharide on Adjuvant Activity of QS-7 Analogues</article-title><source>J. Org. Chem.</source><year>2020</year><volume>85</volume><fpage>15837</fpage><lpage>15848</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.0c00359</pub-id><pub-id pub-id-type="pmid">32463234</pub-id></element-citation></ref><ref id="B113-vaccines-09-00222"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R.C.</given-names></name></person-group><article-title>Quillaja saponin adjuvants: Derivatives formed under sub-optimal conditions</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>3237</fpage><lpage>3238</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00298-0</pub-id><pub-id pub-id-type="pmid">12213391</pub-id></element-citation></ref><ref id="B114-vaccines-09-00222"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slovin</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Ragupathi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jefferson</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Diani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wilton</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Spassova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Clausen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: A study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>3114</fpage><lpage>3122</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.01.072</pub-id><pub-id pub-id-type="pmid">15837210</pub-id></element-citation></ref><ref id="B115-vaccines-09-00222"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Thogaripally</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>S.M.</given-names></name></person-group><article-title>Synthesis of QS-21-based immunoadjuvants</article-title><source>J. Org. Chem.</source><year>2013</year><volume>78</volume><fpage>11525</fpage><lpage>11534</lpage><pub-id pub-id-type="doi">10.1021/jo402118j</pub-id><pub-id pub-id-type="pmid">24147602</pub-id><pub-id pub-id-type="pmcid">PMC3937867</pub-id></element-citation></ref><ref id="B116-vaccines-09-00222"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Devalankar</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>S.M.</given-names></name></person-group><article-title>Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide</article-title><source>J. Org. Chem.</source><year>2016</year><volume>81</volume><fpage>9560</fpage><lpage>9566</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.6b00922</pub-id><pub-id pub-id-type="pmid">27709937</pub-id><pub-id pub-id-type="pmcid">PMC6488304</pub-id></element-citation></ref><ref id="B117-vaccines-09-00222"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>&#352;kalamera</surname><given-names>&#272;.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>S.M.</given-names></name></person-group><article-title>Synthesis and evaluation of a QS-17/18-based vaccine adjuvant</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>1669</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01997</pub-id><pub-id pub-id-type="pmid">30656932</pub-id><pub-id pub-id-type="pmcid">PMC6492282</pub-id></element-citation></ref><ref id="B118-vaccines-09-00222"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Skalamera</surname><given-names>&#272;.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>S.M.</given-names></name></person-group><article-title>Synthesis and evaluation of QS-7-based vaccine adjuvants</article-title><source>ACS Infect. Dis.</source><year>2019</year><volume>5</volume><fpage>974</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00039</pub-id><pub-id pub-id-type="pmid">30920199</pub-id><pub-id pub-id-type="pmcid">PMC6848976</pub-id></element-citation></ref><ref id="B119-vaccines-09-00222"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name></person-group><article-title>Structural Effect on Adjuvanticity of Saponins</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><fpage>3290</fpage><lpage>3297</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b02063</pub-id><pub-id pub-id-type="pmid">32101001</pub-id><pub-id pub-id-type="pmcid">PMC8832471</pub-id></element-citation></ref><ref id="B120-vaccines-09-00222"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rokutani</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mihashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>R.</given-names></name></person-group><article-title>Studies on the constituents of Momordica cochinchinensis SPRENG. I. Isolation and characterization of the seed saponins, momordica saponins I and II</article-title><source>Chem. Pharm. Bull.</source><year>1985</year><volume>33</volume><fpage>464</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1248/cpb.33.464</pub-id></element-citation></ref><ref id="B121-vaccines-09-00222"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walkowicz</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Fernandez-Tejada</surname><given-names>A.</given-names></name><name name-style="western"><surname>George</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corzana</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jimenez-Barbero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ragupathi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Quillaja saponin variants with central glycosidic linkage modifications exhibit distinct conformations and adjuvant activities</article-title><source>Chem. Sci.</source><year>2016</year><volume>7</volume><fpage>2371</fpage><lpage>2380</lpage><pub-id pub-id-type="doi">10.1039/C5SC02978C</pub-id><pub-id pub-id-type="pmid">27014435</pub-id><pub-id pub-id-type="pmcid">PMC4800320</pub-id></element-citation></ref><ref id="B122-vaccines-09-00222"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuentes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ruiz-de-Angulo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sacrist&#225;n</surname><given-names>N.</given-names></name><name name-style="western"><surname>Navo</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Jim&#233;nez-Os&#233;s</surname><given-names>G.</given-names></name><name name-style="western"><surname>Anguita</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Tejada</surname><given-names>A.</given-names></name></person-group><article-title>Replacing the rhamnose&#8211;xylose moiety of QS-21 with simpler terminal disaccharide units attenuates adjuvant activity in truncated saponin variants</article-title><source>Chem. Eur. J.</source><year>2020</year><pub-id pub-id-type="doi">10.1002/chem.202004705</pub-id><pub-id pub-id-type="pmcid">PMC7986102</pub-id><pub-id pub-id-type="pmid">33236801</pub-id></element-citation></ref><ref id="B123-vaccines-09-00222"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Skalamera</surname><given-names>&#272;.</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name></person-group><article-title>Vaccine adjuvants derivatized from Momordica saponins I and II</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>9976</fpage><lpage>9982</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01511</pub-id><pub-id pub-id-type="pmid">31657920</pub-id><pub-id pub-id-type="pmcid">PMC6856410</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="vaccines-09-00222-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Natural saponin adjuvant QS-21.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g001.jpg"/></fig><fig id="vaccines-09-00222-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Natural <italic toggle="yes">QS</italic> saponins QS-7, QS-17, and QS-18.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g002.jpg"/></fig><fig id="vaccines-09-00222-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Immunostimulating natural saponins.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g003.jpg"/></fig><fig id="vaccines-09-00222-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Groups of female BALB/c mice were immunized by the subcutaneous route (s.c.) with OVA (20 &#181;g) alone or with QS-21 (20 &#181;g), or a synthetic saponin (50 &#956;g). IgG2a/IgG1 ratios are expressed as mean &#177; SEM. Statistical significance was evaluated by <italic toggle="yes">t</italic> tests (with unpaired, nonparametric, and Mann-Whitney test). ** <italic toggle="yes">p</italic> &lt; 0.01 compared with the group of OVA alone, and # <italic toggle="yes">p</italic> &lt; 0.05 compared between the indicated groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g004.jpg"/></fig><fig id="vaccines-09-00222-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Synthesized <italic toggle="yes">QS</italic> analogs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g005.jpg"/></fig><fig id="vaccines-09-00222-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Structural similarity between <italic toggle="yes">Momordica</italic> saponins (MS) and de-acylated QS-17/18 and MS derivatization.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g006.jpg"/></fig><fig id="vaccines-09-00222-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Serum IgG, IgG1, and IgG2a anti-OVA response in mice immunized by the s.c. route with OVA alone or with GPI-0100 or a saponin adjuvant. Mice were immunized on days 0, 14, and 28. Serum samples were collected prior to each immunization and at 6 weeks following the initial immunization. Values are expressed as mean &#177; SEM. * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, and *** <italic toggle="yes">p</italic> &lt; 0.001 compared with mice immunized with OVA alone.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g007a.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g007b.jpg"/></fig><fig id="vaccines-09-00222-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Semi-synthetic MS derivative VSA-2. Mice were immunized by the s.c. route with rHagB alone or with GPI-0100 or a saponin adjuvant on days 0, 14, and 28. Serum samples were collected prior to each immunization and at 6 weeks after the initial immunization. IgG2a/IgG1. Values are expressed as mean &#177; SD. Statistical significance compared with rHagB + VSA-2 (<bold>21</bold>). Statistical significance was evaluated by <italic toggle="yes">t</italic> tests (with unpaired, nonparametric, and Mann&#8722;Whitney test). * <italic toggle="yes">p</italic> &lt; 0.05; ** <italic toggle="yes">p</italic> &lt; 0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g008a.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g008b.jpg"/></fig><fig id="vaccines-09-00222-f009" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Synthetic <italic toggle="yes">QS</italic> isomeric analogs having different stereocenters.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00222-g009.jpg"/></fig></floats-group></article></pmc-articleset>